

BARNARD, CHRISTINE (id #2015, dob: 08/17/1954)

Medical Records - CONFIDENTIAL

FROM: CO - Colorado Center of Medical Excellence
Giselle R
4700 HALE PKWY STE. 300, DENVER, CO 80220-4045
Phone: (720) 320-2061
Fax: (303) 388-6957

TO:

Name: BARNARD, CHRISTINE

DOB: 08/17/1954

Date Range: 01/01/2021 to 03/18/2021

This document contains the following records of the patient:

- **Clinical Documents**
- **Lab Results**

This fax may contain sensitive and confidential personal health information that is being sent for the sole use of the intended recipient. Unintended recipients are directed to securely destroy any materials received. You are hereby notified that the unauthorized disclosure or other unlawful use of this fax or any personal health information is prohibited. To the extent patient information contained in this fax is subject to 42 CFR Part 2, this regulation prohibits unauthorized disclosure of these records.

If you received this fax in error, please visit www.athenahealth.com/NotMyFax to notify the sender and confirm that the information will be destroyed. If you do not have internet access, please call 1-888-482-8436 to notify the sender and confirm that the information will be destroyed. Thank you for your attention and cooperation. [ID:2015-A-14239]

BARNARD, CHRISTINE (id #2015, dob: 08/17/1954)

Clinical Documents

Hematology and Oncology - Initial Visit - David Camidge, UCHealth - 03/18/2021

Encounter Summary for Christine Barnard

Most Recent Encounter

David Ross Camidge, MD PhD: 1665 Aurora Ct, ACP, Mail Stop F704, Aurora, CO 80045, Ph. tel:+1-720-848-0300

Reason for Visit

<ul style="list-style-type: none"> New Patient Consult Consultation (Routine): 	Reason	Comments				
	Status	Reason	Specialty	Diagnoses / Procedures	Referred By Contact	Referred To Contact
	Closed	Oncology Lung	Hematology and Oncology	Diagnoses Non-small cell carcinoma of left lung, stage 4 (HC code)	Carson, Robert I, MD 155 S. Madison St. Suite 210 Denver, CO 80209	Camidge, David Ross, MD PhD 1665 Aurora Ct ACP, Mail Stop F704 Aurora, CO 80045 Phone: 720-848-0300 Fax: 720-848-0360

Encounter Details

Date	Type	Department	Care Team	Description
01/31/2017	Initial Visit	UCHealth University of Colorado Cancer Center - Anschutz Medical Campus Anschutz Cancer Pavilion 1665 Aurora Court, 3rd Floor Aurora, CO 80045-2548 720-848-3532	Camidge, David Ross, MD PhD 1665 Aurora Ct ACP, Mail Stop F704 Aurora, CO 80045 720-848-0300 720-848-0360 (Fax)	Non-small cell carcinoma of left lung, stage 4 (HC code) (Primary Dx); Adenocarcinoma of lung, stage 4, unspecified laterality (HC code)

Social History

Tobacco Use	Types	Packs/Day	Years Used	Date
Never Smoker				
Smokeless Tobacco: Never Used				
Alcohol Use	Drinks/Week	oz/Week	Comments	
Yes	1 Glasses of wine	1.0		
Sex Assigned at Birth	Date Recorded			
Female				
documented as of this encounter				

BARNARD, CHRISTINE (id #2015, dob: 08/17/1954)

Last Filed Vital Signs

Vital Sign	Reading	Time Taken	Comments
Blood Pressure	115/83	01/31/2017 2:26 PM MST	
Pulse	79	01/31/2017 2:26 PM MST	
Temperature	36.9 A?C (98.4 A?F)	01/31/2017 2:26 PM MST	
Respiratory Rate	16	01/31/2017 2:26 PM MST	
Oxygen Saturation	95%	01/31/2017 2:26 PM MST	
Inhaled Oxygen Concentration	-	-	
Weight	58.7 kg (129 lb 4.8 oz)	01/31/2017 2:27 PM MST	with shoes off and verify by RN
Height	162.6 cm (5' 4")	01/31/2017 2:27 PM MST	with shoes off and verify by RN
Body Mass Index documented in this encounter	22.19	01/31/2017 2:27 PM MST	

Progress Notes

- Ng, Terry L - 01/31/2017 2:30 PM MST:

Formatting of this note might be different from the original.

Assessment and Plan:

ICD-10-CM

1. Adenocarcinoma of lung, stage 4 (HC code) C34.90
2. Non-small cell carcinoma of left lung, stage 4 (HC code) C34.92

Medications Placed This Encounter

Medications

- a?? traMADol (ULTRAM) 50 mg tablet
 - a?? citalopram (CELEXA) 10 mg tablet
 - a?? traZODone (DESYREL) 50 mg tablet
- There are no discontinued medications.

62 yo F with newly diagnosed Stage IVA ALK rearranged NSCLC. Post-wedge resection of superior LUL and superior LLL. She has residual nodules involving visceral and parietal pleura -- biopsy confirmed adenoca.

ALK FISH test positive for ALK gene rearrangement

ECOG 0

Has not received any systemic cancer therapy yet

MRI Brain (01/31/17) is negative (actual report pending)

Treatment options include standard of care 1st line crizotinib vs. 1st line brigatinib in ALTA-1L study. She should be eligible for ALTA-1L study as long as she has measurable disease per RECIST criteria 1.1. As discussed with Christine and Steve (husband), Brigatinib acts on a broader profile of resistance mechanisms and much better CNS penetration. In the second line setting, after progression on crizotinib, PFS was 15.6 months. Brigatinib is poised to be licensed by FDA in first quarter of 2017 for ALK+ NSCLC in the SECOND LINE. ALTA-1L is a phase 3 randomized trial testing brigatinib vs. crizotinib in first line.

Plan:

1. Consented for ALTA-1L
2. Baseline scan per study including CT chest with contrast since she has had lung surgery since her initial scans.
3. Provided she has measurable disease and meets other study eligibility criteria, patient would like to enroll on Ariad ALTA-1L, a phase 3, RCT with 1:1 randomization to brigatinib or crizotinib.

ECOG performance status - (0) Fully active, able to carry on all predisease performance without restriction

Subjective:

Patient ID: Christine Barnard is a 62 y.o. female who presents to Gastrointestinal & Surgical Oncology for second opinion for newly diagnosed ALK+ NSCLC

HPI

Stage IVA NSCLC, first Dx in 01/16/17, presenting with left lower chest wall pain.

Disease sites at dx: LUL, LLL, pleura

BARNARD, CHRISTINE (id #2015, dob: 08/17/1954)

Histology: superior LUL wedge (well diff adenoca, acinar); sup LLL wedge (well diff adenoca, acinar; diffuse pleural nodularity); pleural biopsy (well diff adenoca) -- TTF-1 and Napsin A+; CK7+; CK20(-)
 Operative report (01/16/17): nodularity noted visceral and parietal pleural surface and diaphragm, nodules in superior LUL and sup LLL/periarota (not invading into aorta)
 Molecular status: ALK FISH+ (01/16/17). Negative for EGFR exon 19-21 / KRAS / ROS-1
 First line Rx: --- from --- to ---, with --- to Rx
 Second line Rx: --- from --- to ---, with --- to Rx
 Current Rx: --- from --- with --- to Rx
 Current disease sites: pleura (LUL major fissure and medial LLL nodule resected) with last brain MRI in 01/31/17 negative

PET/CT (12/27/16): LUL major fissure nodule (1.1 x 0.8 cm) SUV 3.7, medial LLL subpleural / periaortic nodule (0.7 x 1.0 cm), small left pleural effusion. Everything else negative.

CT chest/abdo (12/16/16): same as PET, nodularity throughout much of left major fissure and LLL nodule

AMB PAIN ASSESSMENT 1/31/2017

Pain Now Yes

Pain Assessment 0-10/ Faces

0-10 (NRS) 2

Pain Descriptors (Words) Pressure

Pain Location Chest

Pain Duration Continuous

Aggravating Deep Breathing

Alleviating (No Data)

CURRENT MEDICATIONS:

Current Outpatient Prescriptions

Medication Sig

a?? citalopram (CELEXA) 10 mg tablet 5 mg daily.

a?? traMADol (ULTRAM) 50 mg tablet 50 mg 2 times daily.

a?? traZODone (DESYREL) 50 mg tablet 50 mg nightly at bedtime.

No current facility-administered medications for this visit.

ALLERGIES: Sulfa (sulfonamide antibiotics); Sulfur; Codeine; and Latex

Past Medical History

Diagnosis Date

a?? Adhesive capsulitis of left shoulder

a?? Benign thyroid cyst 12/16/2016

right thyroid lobe, 0.8 cm simple cyst

a?? Depression

a?? Fibromyalgia 2001

a?? GERD (gastroesophageal reflux disease)

a?? Insomnia

a?? Iron deficiency anemia

a?? Thyroid nodule

Past Surgical History

Procedure Laterality Date

a?? Cesarean section N/A

3 sections

a?? Bunionectomy 2014

a?? Rhinoplasty 1973

Family History

Problem Relation Age of Onset

a?? Stroke Mother 87

a?? Diabetes Mother

a?? Heart failure Mother

a?? Melanoma Father

a?? Heart attack Brother 30

a?? Heart attack Brother 43

Social History

Social History

a?? Marital status: Married

Spouse name: N/A

a?? Number of children: N/A

a?? Years of education: N/A

Occupational History

BARNARD, CHRISTINE (id #2015, dob: 08/17/1954)

a?? Data Manager
Colorado Academy

Social History Main Topics

a?? Smoking status: Never Smoker
a?? Smokeless tobacco: Never Used
a?? Alcohol use 0.6 oz/week
1 Glasses of wine per week
a?? Drug use: No
a?? Sexual activity: Not on file

Other Topics Concern

a?? Not on file

Social History Narrative

Data Manager for Colorado Academy
Lives with Husband in Littleton, CO
Husband is a semi-retired chemist
Independent functionally
Walked 3 miles / day until recent surgery -- limited due to surgical site pain

PS 0

left chest wall pain, Gr. 1
Thoracic surgical site pain, Gr. 1

Nil otherwise, except:

Review of Systems

Constitutional: Negative.
HENT: Negative.
Eyes: Negative.
Respiratory: Negative.
Cardiovascular: Negative.
Gastrointestinal: Negative.
Musculoskeletal: Negative.
Skin: Negative.
Neurological: Negative.
Psychiatric/Behavioral: Negative.

Objective:

Vital Signs:

Visit Vitals

a?? BP 115/83
a?? Pulse 79
a?? Temp 36.9 A?C (98.4 A?F) (Temporal Artery)
a?? Resp 16
a?? Ht 1.626 m (5' 4")
Comment: with shoes off and verify by RN
a?? Wt 58.7 kg (129 lb 4.8 oz)
Comment: with shoes off and verify by RN
a?? SpO2 95%
a?? BMI 22.19 kg/m2

Vital Signs from last encounter:

Wt Readings from Last 1 Encounters:

01/31/17 58.7 kg (129 lb 4.8 oz)

BP Readings from Last 1 Encounters:

01/31/17 115/83

Temp Readings from Last 1 Encounters:

01/31/17 36.9 A?C (98.4 A?F) (Temporal Artery)

Pulse Readings from Last 1 Encounters:

01/31/17 79

SpO2 Readings from Last 1 Encounters:

01/31/17 95%

Resp Readings from Last 1 Encounters:

BARNARD, CHRISTINE (id #2015, dob: 08/17/1954)

01/31/17 16

Vital Signs from last three (3) encounters:

Wt Readings from Last 3 Encounters:

01/31/17 58.7 kg (129 lb 4.8 oz)

BP Readings from Last 3 Encounters:

01/31/17 115/83

Temp Readings from Last 3 Encounters:

01/31/17 36.9 A°C (98.4 A°F) (Temporal Artery)

Pulse Readings from Last 3 Encounters:

01/31/17 79

SpO2 Readings from Last 3 Encounters:

01/31/17 95%

Resp Readings from Last 3 Encounters:

01/31/17 16

Physical Exam

Constitutional: She is oriented to person, place, and time. She appears well-developed and well-nourished. No distress.

HENT:

Head: Normocephalic and atraumatic.

Mouth/Throat: Oropharynx is clear and moist. No oropharyngeal exudate.

Eyes: Conjunctivae and EOM are normal. Pupils are equal, round, and reactive to light. No scleral icterus.

Neck: Normal range of motion. Neck supple. No JVD present.

Cardiovascular: Normal rate, regular rhythm, normal heart sounds and intact distal pulses. Exam reveals no gallop and no friction rub.

No murmur heard.

Pulmonary/Chest: Effort normal and breath sounds normal. No stridor. No respiratory distress. She has no wheezes. She has no rales.

Abdominal: Soft. Bowel sounds are normal. There is no tenderness. There is no rebound and no guarding.

Musculoskeletal: Normal range of motion. She exhibits no edema, tenderness or deformity.

Lymphadenopathy:

She has no cervical adenopathy.

Neurological: She is alert and oriented to person, place, and time.

Skin: Skin is warm and dry. She is not diaphoretic.

Psychiatric: She has a normal mood and affect. Her behavior is normal. Judgment and thought content normal.

Vitals reviewed.

DATA:

No results found for any previous visit.

TIME/COUNSELING:

N/A

Terry Ng

DR CAMIDGE - I saw the patient with the resident/fellow, confirmed the findings and agreed the plan. I personally spent a total of 60 minutes, of that 35 minutes was counselling/cordination of patient care. We discussed stage IV alk+ disease - option for ALTA-IL or crizotinib - will depend on measurability of pleural plaques - continue with screening - dr feiner informed by email.

Electronically signed by Camidge, D Ross, MD PhD at 02/02/2017 12:25 PM MST

documented in this encounter

Plan of Treatment

Not on file

documented as of this encounter

BARNARD, CHRISTINE (id #2015, dob: 08/17/1954)

Visit Diagnoses

Diagnosis
Non-small cell carcinoma of left lung, stage 4 (HC code) - Primary
Adenocarcinoma of lung, stage 4, unspecified laterality (HC code)
documented in this encounter

Demographics

Sex:	Female	Ethnicity:	Not Hispanic or Latino
DOB:	08/17/1954	Race:	White
Preferred language:	English	Marital status:	Married

Contact: 4401 MARIGOLD LANE, LITTLETON, CO 80123, USA, Ph. tel:+1-720-480-7411

Care Team Members

Primary Care Provider	
Cara H Dawson, MD	Ph. tel:+1-720-320-2061

Lab - Lab Only - Melissa Jaramillo, UCHealth - 03/18/2021

Encounter Summary for Christine Barnard

Most Recent Encounter

Melissa Anne Jaramillo, MA: University Of CO HealthCO

Encounter Details

Date	Type	Department	Care Team	Description
02/08/2017	Lab Only	UCHealth Laboratory - University of Colorado Hospital Anschutz Cancer Pavilion 1665 Aurora Court- 2nd FL Aurora, CO 80045-2548 720-848-0300	Rossi, Candice Brooke, NP 1665 Aurora Ct Campus Box F704 Aurora, CO 80045 720-848-0300 720-848-1587 (Fax) Jaramillo, Melissa Anne, MA University Of CO Health CO	Examination of participant in clinical trial

Social History

Tobacco Use	Types	Packs/Day	Years Used	Date
Never Smoker				
Smokeless Tobacco: Never Used				
Alcohol Use	Drinks/Week	oz/Week	Comments	
Yes	1 Glasses of wine	1.0		
Sex Assigned at Birth	Date Recorded			
Female				
documented as of this encounter				

BARNARD, CHRISTINE (id #2015, dob: 08/17/1954)

Plan of Treatment

Not on file

documented as of this encounter

Procedures

Procedure Name	Priority	Date/Time	Associated Diagnosis	Comments
BILIRUBIN DIRECT PANEL	Routine	02/08/2017 8:09 AM MST	Examination of participant in clinical trial	Results for this procedure are in the results section.
CBC WITH MANUAL DIFF IF AUTO FAILS (PERFORMABLE)	Routine	02/08/2017 8:09 AM MST	Examination of participant in clinical trial	Results for this procedure are in the results section.
CANCER ANTIGEN 27.29	Routine	02/08/2017 8:09 AM MST	Examination of participant in clinical trial	Results for this procedure are in the results section.
CANCER ANTIGEN 19-9 (CA-GI)	Routine	02/08/2017 8:09 AM MST	Examination of participant in clinical trial	Results for this procedure are in the results section.
INSULIN	Routine	02/08/2017 8:09 AM MST	Examination of participant in clinical trial	Results for this procedure are in the results section.
CBC WITH MANUAL DIFF IF AUTO FAILS (ORDERABLE)	Routine	02/08/2017 8:09 AM MST	Examination of participant in clinical trial	Results for this procedure are in the results section.
CANCER ANTIGEN 125	Routine	02/08/2017 8:09 AM MST	Examination of participant in clinical trial	Results for this procedure are in the results section.
URIC ACID SERUM	Routine	02/08/2017 8:09 AM MST	Examination of participant in clinical trial	Results for this procedure are in the results section.
PHOSPHORUS SERUM/PLASMA	Routine	02/08/2017 8:09 AM MST	Examination of participant in clinical trial	Results for this procedure are in the results section.
MAGNESIUM SERUM	Routine	02/08/2017 8:09 AM MST	Examination of participant in clinical trial	Results for this procedure are in the results section.
LIPASE	Routine	02/08/2017 8:09 AM MST	Examination of participant in clinical trial	Results for this procedure are in the results section.
LACTATE DEHYDROGENASE (LDH)	Routine	02/08/2017 8:09 AM MST	Examination of participant in clinical trial	Results for this procedure are in the results section.
CREATINE KINASE	Routine	02/08/2017 8:09 AM MST	Examination of participant in clinical trial	Results for this procedure are in the results section.
CARCINOEMBRYONIC ANTIGEN	Routine	02/08/2017 8:09 AM MST	Examination of participant in clinical trial	Results for this procedure are in the results section.
AMYLASE SERUM	Routine	02/08/2017 8:09 AM MST	Examination of participant in clinical trial	Results for this procedure are in the results section.
COMPREHENSIVE METABOLIC PANEL	Routine	02/08/2017 8:09 AM MST	Examination of participant in clinical trial	Results for this procedure are in the results section.

documented in this encounter

Results

- CBC with Auto Differential (02/08/2017 8:09 AM MST):

Component	Value	Ref Range	Performed At	Pathologist Signature
White Blood Cell Count	7.2	4.0 - 11.1 10 ⁹ /L	ANSCHUTZ MEDICAL CAMPUS LAB, AURORA, CO	
Red Blood Cell Count	4.82	4.18 - 5.64 10 ¹² /L	ANSCHUTZ MEDICAL CAMPUS LAB, AURORA, CO	
Hemoglobin	14.7	12.1 - 16.3 g/dL	ANSCHUTZ MEDICAL CAMPUS LAB, AURORA, CO	

BARNARD, CHRISTINE (id #2015, dob: 08/17/1954)

Hematocrit	44.6	35.7 - 46.7 %	ANSCHUTZ MEDICAL CAMPUS LAB, AURORA, CO
Mean Corpuscular Volume	92.5	80.0 - 100.0 fL	ANSCHUTZ MEDICAL CAMPUS LAB, AURORA, CO
Mean Corpuscular Hemoglobin	30.5	27.5 - 35.1 pg	ANSCHUTZ MEDICAL CAMPUS LAB, AURORA, CO
Mean Corpuscular Hemoglobin Concentration	33.0	32.0 - 36.0 g/dL	ANSCHUTZ MEDICAL CAMPUS LAB, AURORA, CO
Platelet Count	259	150 - 400 10 ⁹ /L	ANSCHUTZ MEDICAL CAMPUS LAB, AURORA, CO
Mean Platelet Volume	9.2 (L)	9.6 - 12.8 fL	ANSCHUTZ MEDICAL CAMPUS LAB, AURORA, CO
Red Cell Distribution Width CV	13.3	11.7 - 14.2 %	ANSCHUTZ MEDICAL CAMPUS LAB, AURORA, CO
Red Cell Distribution Width SD	44.8	37.1 - 48.8 fL	ANSCHUTZ MEDICAL CAMPUS LAB, AURORA, CO
NRBC Percent	0.0	0 %	ANSCHUTZ MEDICAL CAMPUS LAB, AURORA, CO
NRBC Absolute	0.00	0 10 ⁹ /L	ANSCHUTZ MEDICAL CAMPUS LAB, AURORA, CO
Segmented Neutrophil Percent	58.9	%	ANSCHUTZ MEDICAL CAMPUS LAB, AURORA, CO
Lymphocyte Percent	24.4	%	ANSCHUTZ MEDICAL CAMPUS LAB, AURORA, CO
Monocytes Percent	9.6	%	ANSCHUTZ MEDICAL CAMPUS LAB, AURORA, CO
Eosinophils Percent	6.3	%	ANSCHUTZ MEDICAL CAMPUS LAB, AURORA, CO
Basophils Percent	0.7	%	ANSCHUTZ MEDICAL CAMPUS LAB, AURORA, CO

BARNARD, CHRISTINE (id #2015, dob: 08/17/1954)

Immature Granulocytes Percent	0.1	%	ANSCHUTZ MEDICAL CAMPUS LAB, AURORA, CO
Neutrophils Absolute	4.2	1.8 - 6.6 10 ⁹ /L	ANSCHUTZ MEDICAL CAMPUS LAB, AURORA, CO
Lymphocyte Absolute	1.8	1.0 - 4.8 10 ⁹ /L	ANSCHUTZ MEDICAL CAMPUS LAB, AURORA, CO
Monocytes Absolute	0.7	0.2 - 0.9 10 ⁹ /L	ANSCHUTZ MEDICAL CAMPUS LAB, AURORA, CO
Eosinophils Absolute	0.5 (H)	0.0 - 0.4 10 ⁹ /L	ANSCHUTZ MEDICAL CAMPUS LAB, AURORA, CO
Basophils Absolute	0.1	0.0 - 0.2 10 ⁹ /L	ANSCHUTZ MEDICAL CAMPUS LAB, AURORA, CO
Immature Granulocytes Absolute	0.0	0.0 - 0.05 10 ⁹ /L	ANSCHUTZ MEDICAL CAMPUS LAB, AURORA, CO

Specimen

Blood - Blood specimen (specimen)

Performing Organization	Address	City/State/ZIP Code	Phone Number
ANSCHUTZ MEDICAL CAMPUS LAB, AURORA, CO	12401 East 17th Avenue Campus Box A022	AURORA, CO 80045	720-848-4401

• Carcinoembryonic Antigen (02/08/2017 8:09 AM MST):

Component	Value	Ref Range	Performed At	Pathologist Signature
Carcinoembryonic Antigen DXI	13.5 (H) Comment: Non-Smoker: A 0.0 - 3.0 ng/mL A A Smoker: A 0.0 - 5.0 ng/mL A	0.0 - 3.0 ng/mL	ANSCHUTZ MEDICAL CAMPUS LAB, AURORA, CO	

Specimen

Blood - Blood specimen (specimen)

Performing Organization	Address	City/State/ZIP Code	Phone Number
ANSCHUTZ MEDICAL CAMPUS LAB, AURORA, CO	12401 East 17th Avenue Campus Box A022	AURORA, CO 80045	720-848-4401

• Cancer Antigen 19-9 (CA-GI) (02/08/2017 8:09 AM MST):

Component	Value	Ref Range	Performed At	Pathologist Signature
-----------	-------	-----------	--------------	-----------------------

BARNARD, CHRISTINE (id #2015, dob: 08/17/1954)

Cancer Antigen 11.5	0.0 - 35.0 U/mL	ANSCHUTZ MEDICAL
199 DXI	Comment:	CAMPUS LAB, AURORA, CO

Patients must possess the ability to express the Lewis blood group antigen or they will be unable to produce the CA 19-9 antigen even in the presence of proven malignancy. A patient with a positive genotype for the Lewis antigen may produce varying levels of CA 19-9 antigen. Phenotyping for the presence of the Lewis blood group antigen may be insufficient to detect true Lewis antigen negative individuals. A

Specimen

Blood - Blood specimen (specimen)

Performing Organization	Address	City/State/ZIP Code	Phone Number
ANSCHUTZ MEDICAL	12401 East 17th Avenue	AURORA, CO 80045	720-848-4401
CAMPUS LAB, AURORA, CO	Campus Box A022		

- Cancer Antigen 27.29 (02/08/2017 8:09 AM MST):

Component	Value	Ref Range	Performed At	Pathologist Signature
CA 27.29	33	<40 U/mL	ANSCHUTZ MEDICAL	
CENT			CAMPUS LAB, AURORA, CO	

Specimen

Blood - Blood specimen (specimen)

Performing Organization	Address	City/State/ZIP Code	Phone Number
ANSCHUTZ MEDICAL	12401 East 17th Avenue	AURORA, CO 80045	720-848-4401
CAMPUS LAB, AURORA, CO	Campus Box A022		

- Cancer Antigen 125 (02/08/2017 8:09 AM MST):

Component	Value	Ref Range	Performed At	Pathologist Signature
Cancer Antigen 125 DXI	206 (H)	0 - 35 U/mL	ANSCHUTZ MEDICAL	
			CAMPUS LAB, AURORA, CO	

Specimen

Blood - Blood specimen (specimen)

Performing Organization	Address	City/State/ZIP Code	Phone Number
ANSCHUTZ MEDICAL	12401 East 17th Avenue	AURORA, CO 80045	720-848-4401
CAMPUS LAB, AURORA, CO	Campus Box A022		

- Insulin (02/08/2017 8:09 AM MST):

Component	Value	Ref Range	Performed At	Pathologist Signature
Insulin	13	2 - 23 uIU/mL	ANSCHUTZ MEDICAL	
			CAMPUS LAB, AURORA, CO	

Specimen

Blood - Blood specimen (specimen)

Performing Organization	Address	City/State/ZIP Code	Phone Number
ANSCHUTZ MEDICAL	12401 East 17th Avenue	AURORA, CO 80045	720-848-4401
CAMPUS LAB, AURORA, CO	Campus Box A022		

- Lipase (02/08/2017 8:09 AM MST):

Component	Value	Ref Range	Performed At	Pathologist Signature
Lipase	44	11 - 82 U/L	ANSCHUTZ MEDICAL	
Serum/Plasma			CAMPUS LAB, AURORA, CO	

BARNARD, CHRISTINE (id #2015, dob: 08/17/1954)

Specimen

Blood - Blood specimen (specimen)

Performing Organization	Address	City/State/ZIP Code	Phone Number
ANSCHUTZ MEDICAL CAMPUS LAB, AURORA, CO	12401 East 17th Avenue Campus Box A022	AURORA, CO 80045	720-848-4401

- Amylase Serum (02/08/2017 8:09 AM MST):

Component	Value	Ref Range	Performed At	Pathologist Signature
Amylase Serum	57	29 - 103 U/L	ANSCHUTZ MEDICAL CAMPUS LAB, AURORA, CO	

Specimen

Blood - Blood specimen (specimen)

Performing Organization	Address	City/State/ZIP Code	Phone Number
ANSCHUTZ MEDICAL CAMPUS LAB, AURORA, CO	12401 East 17th Avenue Campus Box A022	AURORA, CO 80045	720-848-4401

- Uric Acid Serum (02/08/2017 8:09 AM MST):

Component	Value	Ref Range	Performed At	Pathologist Signature
Uric Acid Serum	4.5	2.3 - 6.6 mg/dL	ANSCHUTZ MEDICAL CAMPUS LAB, AURORA, CO	

Specimen

Blood - Blood specimen (specimen)

Performing Organization	Address	City/State/ZIP Code	Phone Number
ANSCHUTZ MEDICAL CAMPUS LAB, AURORA, CO	12401 East 17th Avenue Campus Box A022	AURORA, CO 80045	720-848-4401

- Creatine Kinase (02/08/2017 8:09 AM MST):

Component	Value	Ref Range	Performed At	Pathologist Signature
Creatine Kinase	49	30 - 223 U/L	ANSCHUTZ MEDICAL CAMPUS LAB, AURORA, CO	

Specimen

Blood - Blood specimen (specimen)

Performing Organization	Address	City/State/ZIP Code	Phone Number
ANSCHUTZ MEDICAL CAMPUS LAB, AURORA, CO	12401 East 17th Avenue Campus Box A022	AURORA, CO 80045	720-848-4401

- Lactate Dehydrogenase (LDH) (02/08/2017 8:09 AM MST):

Component	Value	Ref Range	Performed At	Pathologist Signature
Lactate Dehydrogenase	201	124 - 271 U/L	ANSCHUTZ MEDICAL CAMPUS LAB, AURORA, CO	

Specimen

Blood - Blood specimen (specimen)

Performing Organization	Address	City/State/ZIP Code	Phone Number
ANSCHUTZ MEDICAL CAMPUS LAB, AURORA, CO	12401 East 17th Avenue Campus Box A022	AURORA, CO 80045	720-848-4401

- Phosphorus Serum/Plasma (02/08/2017 8:09 AM MST):

Component	Value	Ref Range	Performed At	Pathologist Signature
Phosphorus Serum/Plasma	3.0	2.5 - 5.0 mg/dL	ANSCHUTZ MEDICAL CAMPUS LAB, AURORA, CO	

Specimen

Blood - Blood specimen (specimen)

Performing Organization	Address	City/State/ZIP Code	Phone Number
-------------------------	---------	---------------------	--------------

BARNARD, CHRISTINE (id #2015, dob: 08/17/1954)

ANSCHUTZ MEDICAL 12401 East 17th Avenue AURORA, CO 80045 720-848-4401
 CAMPUS LAB, AURORA, CO
 Campus Box A022

• Magnesium Serum (02/08/2017 8:09 AM MST):

Component	Value	Ref Range	Performed At	Pathologist Signature
Magnesium Serum/Plasma	2.1	1.6 - 2.5 mg/dL	ANSCHUTZ MEDICAL CAMPUS LAB, AURORA, CO	

Specimen

Blood - Blood specimen (specimen)

Performing Organization	Address	City/State/ZIP Code	Phone Number
ANSCHUTZ MEDICAL CAMPUS LAB, AURORA, CO	12401 East 17th Avenue Campus Box A022	AURORA, CO 80045	720-848-4401

• Bilirubin Direct Panel (02/08/2017 8:09 AM MST):

Component	Value	Ref Range	Performed At	Pathologist Signature
Bilirubin Total	0.4	0.1 - 1.3 mg/dL	ANSCHUTZ MEDICAL CAMPUS LAB, AURORA, CO	
Bilirubin Direct	0.1	0.0 - 0.2 mg/dL	ANSCHUTZ MEDICAL CAMPUS LAB, AURORA, CO	
Bilirubin Indirect	0.3	0.0 - 1.0 mg/dL	ANSCHUTZ MEDICAL CAMPUS LAB, AURORA, CO	

Specimen

Blood - Blood specimen (specimen)

Performing Organization	Address	City/State/ZIP Code	Phone Number
ANSCHUTZ MEDICAL CAMPUS LAB, AURORA, CO	12401 East 17th Avenue Campus Box A022	AURORA, CO 80045	720-848-4401

• Comprehensive Metabolic Panel (02/08/2017 8:09 AM MST):

Component	Value	Ref Range	Performed At	Pathologist Signature
Sodium Serum/Plasma	141	133 - 145 mmol/L	ANSCHUTZ MEDICAL CAMPUS LAB, AURORA, CO	
Potassium Serum/Plasma	4.5	3.5 - 5.1 mmol/L	ANSCHUTZ MEDICAL CAMPUS LAB, AURORA, CO	
Chloride Serum/Plasma	107	98 - 108 mmol/L	ANSCHUTZ MEDICAL CAMPUS LAB, AURORA, CO	
Carbon Dioxide	25	21 - 31 mmol/L	ANSCHUTZ MEDICAL CAMPUS LAB, AURORA, CO	
Anion Gap	9	4 - 16 mmol/L	ANSCHUTZ MEDICAL CAMPUS LAB, AURORA, CO	
Glucose Serum/Plasma	80	70 - 199 mg/dL	ANSCHUTZ MEDICAL CAMPUS LAB, AURORA, CO	

BARNARD, CHRISTINE (id #2015, dob: 08/17/1954)

Blood Urea Nitrogen	17	7 - 25 mg/dL	ANSCHUTZ MEDICAL CAMPUS LAB, AURORA, CO
Creatinine Serum/Plasma	0.65	0.60 - 1.20 mg/dL	ANSCHUTZ MEDICAL CAMPUS LAB, AURORA, CO
Estimated GFR	>60 Comment: eGFR estimated by IDMS-traceable MDRD Study equation for ages 18-70 years. A Not validated for use during pregnancy, acute illness, or in people with unique diets or abnormal muscle mass.	>=60 mL/min/1.73 "square meters"	ANSCHUTZ MEDICAL CAMPUS LAB, AURORA, CO
Estimated GFR (incl. race term)	>60 Comment: eGFR estimated by IDMS-traceable MDRD Study equation for ages 18-70 years. A Not validated for use during pregnancy, acute illness, or in people with unique diets or abnormal muscle mass.	>=60 mL/min/1.73 "square meters"	ANSCHUTZ MEDICAL CAMPUS LAB, AURORA, CO
Calcium Serum/Plasma	9.6	8.6 - 10.3 mg/dL	ANSCHUTZ MEDICAL CAMPUS LAB, AURORA, CO
Bilirubin Total	0.4	0.1 - 1.3 mg/dL	ANSCHUTZ MEDICAL CAMPUS LAB, AURORA, CO
Alkaline Phosphatase Total	126 (H)	39 - 117 U/L	ANSCHUTZ MEDICAL CAMPUS LAB, AURORA, CO
Alanine Aminotransferase	15	7 - 52 U/L	ANSCHUTZ MEDICAL CAMPUS LAB, AURORA, CO
Aspartate Aminotransferase	16	12 - 39 U/L	ANSCHUTZ MEDICAL CAMPUS LAB, AURORA, CO
Protein Total Serum/Plasma	7.0	6.4 - 8.9 g/dL	ANSCHUTZ MEDICAL CAMPUS LAB, AURORA, CO
Albumin	4.2	3.5 - 5.7 g/dL	ANSCHUTZ MEDICAL CAMPUS LAB, AURORA, CO

Specimen

Blood - Blood specimen (specimen)

Performing Organization	Address	City/State/ZIP Code	Phone Number
ANSCHUTZ MEDICAL CAMPUS LAB, AURORA, CO	12401 East 17th Avenue Campus Box A022	AURORA, CO 80045	720-848-4401

BARNARD, CHRISTINE (id #2015, dob: 08/17/1954)

Visit Diagnoses

Diagnosis

Examination of participant in clinical trial
documented in this encounter

Demographics

Sex:	Female	Ethnicity:	Not Hispanic or Latino
DOB:	08/17/1954	Race:	White
Preferred language:	English	Marital status:	Married
Contact:	4401 MARIGOLD LANE, LITTLETON, CO 80123, USA, Ph. tel:+1-720-480-7411		

Care Team Members

Primary Care Provider	
Cara H Dawson, MD	Ph. tel:+1-720-320-2061

Lab - Lab Only - UCHealth - 03/18/2021

Encounter Summary for Christine Barnard

Most Recent Encounter

Hrh Lab Express Provider: University of Co HealthCO

Encounter Details

Date	Type	Department	Care Team	Description
03/15/2021	Lab Only	UCHealth Laboratory - Highlands Ranch Hospital 1500 Park Central Drive Highlands Ranch, CO 80129		Adenocarcinoma of lung, stage 4, unspecified laterality (HC code)

Social History

Tobacco Use	Types	Packs/Day	Years Used	Date
Never Smoker				
Smokeless Tobacco: Never Used				
Alcohol Use	Drinks/Week	oz/Week		Comments
Yes				1/week
Sex Assigned at Birth	Date Recorded			
Female	10/12/2020 1:33 PM MDT			
COVID-19 Exposure	Response			Date Recorded
In the last 14 days, have you had close contact (more than 15 minutes at a distance of six feet or less) with someone who is confirmed or suspected to have Coronavirus / COVID-19? documented as of this encounter	No / Unsure			3/15/2021 1:55 PM MDT

Plan of Treatment

Not on file
documented as of this encounter

BARNARD, CHRISTINE (id #2015, dob: 08/17/1954)

Procedures

Procedure Name	Priority	Date/Time	Associated Diagnosis	Comments
CBC, ONCOLOGY	STAT	03/15/2021 8:10 AM MDT	Adenocarcinoma of lung, stage 4, unspecified laterality (HC code)	Results for this procedure are in the results section.
CANCER ANTIGEN 125	Routine	03/15/2021 8:10 AM MDT	Adenocarcinoma of lung, stage 4, unspecified laterality (HC code)	Results for this procedure are in the results section.
LIPASE	STAT	03/15/2021 8:10 AM MDT	Adenocarcinoma of lung, stage 4, unspecified laterality (HC code)	Results for this procedure are in the results section.
CREATINE KINASE	STAT	03/15/2021 8:10 AM MDT	Adenocarcinoma of lung, stage 4, unspecified laterality (HC code)	Results for this procedure are in the results section.
CARCINOEMBRYONIC ANTIGEN	Routine	03/15/2021 8:10 AM MDT	Adenocarcinoma of lung, stage 4, unspecified laterality (HC code)	Results for this procedure are in the results section.
AMYLASE SERUM	STAT	03/15/2021 8:10 AM MDT	Adenocarcinoma of lung, stage 4, unspecified laterality (HC code)	Results for this procedure are in the results section.
COMPREHENSIVE METABOLIC PANEL	STAT	03/15/2021 8:10 AM MDT	Adenocarcinoma of lung, stage 4, unspecified laterality (HC code)	Results for this procedure are in the results section.

documented in this encounter

Results

- Lipase (03/15/2021 8:10 AM MDT):

Component	Value	Ref Range	Performed At	Pathologist Signature
Lipase Serum/Plasma	137	23 - 300 U/L	HRH HOSPITAL LAB	

Specimen

Blood - Blood specimen (specimen)

Performing Organization	Address	City/State/ZIP Code	Phone Number
HRH HOSPITAL LAB	1500 PARK CENTRAL DRIVE	HIGHLANDS RANCH, CO 80129	

- Amylase serum (03/15/2021 8:10 AM MDT):

Component	Value	Ref Range	Performed At	Pathologist Signature
Amylase Serum	92	30 - 110 U/L	HRH HOSPITAL LAB	

Specimen

Blood - Blood specimen (specimen)

Performing Organization	Address	City/State/ZIP Code	Phone Number
HRH HOSPITAL LAB	1500 PARK CENTRAL DRIVE	HIGHLANDS RANCH, CO 80129	

- Creatinine Kinase (03/15/2021 8:10 AM MDT):

Component	Value	Ref Range	Performed At	Pathologist Signature
Creatine Kinase	606 (H)	30 - 223 U/L	HRH HOSPITAL LAB	

Specimen

Blood - Blood specimen (specimen)

Performing Organization	Address	City/State/ZIP Code	Phone Number
HRH HOSPITAL LAB	1500 PARK CENTRAL DRIVE	HIGHLANDS RANCH, CO 80129	

- Comprehensive metabolic panel (03/15/2021 8:10 AM MDT):

Component	Value	Ref Range	Performed At	Pathologist Signature
Sodium Serum/Plasma	140	134 - 145 mmol/L	HRH HOSPITAL LAB	

BARNARD, CHRISTINE (id #2015, dob: 08/17/1954)

Potassium Serum/Plasma	4.1	3.5 - 5.1 mmol/L	HRH HOSPITAL LAB
Chloride Serum/Plasma	107	98 - 109 mmol/L	HRH HOSPITAL LAB
Carbon Dioxide	25	22 - 30 mmol/L	HRH HOSPITAL LAB
Anion Gap	8	4 - 15 mmol/L	HRH HOSPITAL LAB
Glucose Serum/Plasma	88	70 - 199 mg/dL	HRH HOSPITAL LAB
Blood Urea Nitrogen	20 (H)	7 - 17 mg/dL	HRH HOSPITAL LAB
Creatinine Serum/Plasma	0.70	0.52 - 1.04 mg/dL	HRH HOSPITAL LAB
Estimated GFR	>90Comment: The IDMS- traceable CKD-EPI equation for ages 18-97 years was used to approximate GFR. This calculation is often unreliable when someone is acutely ill or pregnant. This estimation assumes that one has an average physique and diet. If necessary, consider ordering cystatin C to further assess renal function and CKD.	>=60 mL/min/1.73 "square meters"	HRH HOSPITAL LAB
Estimated GFR (incl. race term)	>90Comment: The IDMS- traceable CKD-EPI equation for ages 18-97 years was used to approximate GFR. This calculation is often unreliable when someone is acutely ill or pregnant. This estimation assumes that one has an average physique and diet. If necessary, consider ordering cystatin C to further assess renal function and CKD.	>=60 mL/min/1.73 "square meters"	HRH HOSPITAL LAB
BUN/Creatinine Ratio	28.6		HRH HOSPITAL LAB
Calcium Serum/Plasma	9.6	8.4 - 10.2 mg/dL	HRH HOSPITAL LAB
Protein Total Serum/Plasma	7.4	6.4 - 8.9 g/dL	HRH HOSPITAL LAB
Albumin	4.5	3.5 - 5.0 g/dL	HRH HOSPITAL LAB
Bilirubin Total	0.6	0.2 - 1.3 mg/dL	HRH HOSPITAL LAB
Alkaline Phosphatase Total	97	38 - 126 U/L	HRH HOSPITAL LAB

BARNARD, CHRISTINE (id #2015, dob: 08/17/1954)

Aspartate Aminotransferase	54	16 - 55 U/L	HRH HOSPITAL LAB
Alanine Aminotransferase	33	<35 U/L	HRH HOSPITAL LAB
Total Globulin	2.9	2.3 - 3.9 g/dL	HRH HOSPITAL LAB
A/G Ratio	1.6	Ratio	HRH HOSPITAL LAB

Specimen

Blood - Blood specimen (specimen)

Performing Organization	Address	City/State/ZIP Code	Phone Number
HRH HOSPITAL LAB	1500 PARK CENTRAL DRIVE	HIGHLANDS RANCH, CO 80129	

• CBC Oncology (03/15/2021 8:10 AM MDT):

Component	Value	Ref Range	Performed At	Pathologist Signature
White Blood Cell Count	4.9	4.0 - 11.1 10 ⁹ /L	HRH HOSPITAL LAB	
Red Blood Cell Count	4.48	4.18 - 5.64 10 ¹² /L	HRH HOSPITAL LAB	
Hemoglobin	13.0	12.1 - 16.3 g/dL	HRH HOSPITAL LAB	
Hematocrit	40.3	35.7 - 46.7 %	HRH HOSPITAL LAB	
Mean Corpuscular Volume	90.0	80.0 - 100.0 fL	HRH HOSPITAL LAB	
Mean Corpuscular Hemoglobin	29.0	27.5 - 35.1 pg	HRH HOSPITAL LAB	
Mean Corpuscular Hemoglobin Concentration	32.3	32.0 - 36.0 g/dL	HRH HOSPITAL LAB	
Platelet Count	206	150 - 400 10 ⁹ /L	HRH HOSPITAL LAB	
Red Cell Distribution Width CV	14.2	11.7 - 14.2 %	HRH HOSPITAL LAB	
NRBC Percent	0.0	0 %	HRH HOSPITAL LAB	
NRBC Absolute	0.00	0 - 0.1 10 ⁹ /L	HRH HOSPITAL LAB	
Segmented Neutrophil Percent	49.5	%	HRH HOSPITAL LAB	
Lymphocyte Percent	37.9	%	HRH HOSPITAL LAB	
Monocytes Percent	9.2	%	HRH HOSPITAL LAB	

BARNARD, CHRISTINE (id #2015, dob: 08/17/1954)

Eosinophils Percent	2.2	%	HRH HOSPITAL LAB
Basophils Percent	0.8	%	HRH HOSPITAL LAB
Immature Granulocytes Percent	0.4	%	HRH HOSPITAL LAB
Neutrophils Absolute	2.4	1.8 - 6.6 10 ⁹ /L	HRH HOSPITAL LAB
Lymphocyte Absolute	1.9	1.0 - 4.8 10 ⁹ /L	HRH HOSPITAL LAB
Monocytes Absolute	0.5	0.2 - 0.9 10 ⁹ /L	HRH HOSPITAL LAB
Eosinophils Absolute	0.1	0.0 - 0.4 10 ⁹ /L	HRH HOSPITAL LAB
Basophils Absolute	0.0	0.0 - 0.2 10 ⁹ /L	HRH HOSPITAL LAB
Immature Granulocytes Absolute	0.0	0.0 - 0.1 10 ⁹ /L	HRH HOSPITAL LAB

Specimen

Blood - Blood specimen (specimen)

Performing Organization	Address	City/State/ZIP Code	Phone Number
HRH HOSPITAL LAB	1500 PARK CENTRAL DRIVE	HIGHLANDS RANCH, CO 80129	

- Cancer Antigen 125 (03/15/2021 8:10 AM MDT):

Component	Value	Ref Range	Performed At	Pathologist Signature
Cancer Antigen 8 125 DXI		0 - 35 U/mL	ANSCHUTZ MEDICAL CAMPUS LAB, AURORA, CO	

Specimen

Blood - Blood specimen (specimen)

Narrative			Performed At
Tested with Access OV Monitor Cancer Antigen 125 assay; other assays' values aren't interchangeable.			ANSCHUTZ MEDICAL CAMPUS LAB, AURORA, CO
Performing Organization	Address	City/State/ZIP Code	Phone Number
ANSCHUTZ MEDICAL	12401 East 17th Avenue	AURORA, CO 80045	720-848-4401

- Carcinoembryonic Antigen (03/15/2021 8:10 AM MDT):

Component	Value	Ref Range	Performed At	Pathologist Signature
Carcinoembryonic Antigen ORTHO	2.2	<=5.0 ng/mL	HRH HOSPITAL LAB	

Specimen

Blood - Blood specimen (specimen)

Performing Organization	Address	City/State/ZIP Code	Phone Number
HRH HOSPITAL LAB	1500 PARK CENTRAL DRIVE	HIGHLANDS RANCH, CO 80129	

documented in this encounter

BARNARD, CHRISTINE (id #2015, dob: 08/17/1954)

Visit Diagnoses

Diagnosis

Adenocarcinoma of lung, stage 4, unspecified laterality (HC code)
documented in this encounter

Additional Health Concerns

Assessment

PHQ-2 Depression Total Score: 0
documented as of this encounter

Noted Time

12/16/2020 8:31 AM MST

Demographics

Sex:	Female	Ethnicity:	Not Hispanic or Latino
DOB:	08/17/1954	Race:	White
Preferred language:	English	Marital status:	Married

Contact: 4401 MARIGOLD LANE, LITTLETON, CO 80123, USA, Ph. tel:+1-720-480-7411

Care Team Members

Primary Care Provider

Cara H Dawson, MD Ph. tel:+1-720-320-2061

Radiology - Hospital Encounter - UCHealth - 03/18/2021

Encounter Summary for Christine Barnard

Most Recent Encounter

Hrh Mr 1: University of Co HealthCO

Reason for Referral

• MRI/CAT Scan (Routine):					
Status	Reason	Specialty	Diagnoses / Procedures	Referred By Contact	Referred To Contact
Denied			Diagnoses	Hall, Francis Killian, MD	
			Adenocarcinoma of lung, stage 4, unspecified laterality (HC code)	12605 E 16th Ave Aurora, CO 80014	
			Procedures	Phone: 720-848-0000	
			MR BRAIN W/VO CONTRAST	Fax: 720-718-0995	

BARNARD, CHRISTINE (id #2015, dob: 08/17/1954)**Reason for Visit**

- MRI/CAT Scan (Routine):

Status	Reason	Specialty	Diagnoses / Procedures	Referred By Contact	Referred To Contact
Denied			Diagnoses Adenocarcinoma of lung, stage 4, unspecified laterality (HC code)	Hall, Francis Killian, MD 12605 E 16th Ave Aurora, CO 80014 Phone: 720-848-0000	
			Procedures MR BRAIN W/WO CONTRAST	Fax: 720-718-0995	

Encounter Details

Date	Type	Department	Care Team	Description
03/15/2021	Hospital Encounter	UCHealth Radiology - Highlands Ranch Hospital 1500 Park Central Drive Highlands Ranch, CO 80129 720-516-1002		Adenocarcinoma of lung, stage 4, unspecified laterality (HC code)

Social History

Tobacco Use	Types	Packs/Day	Years Used	Date
Never Smoker				
Smokeless Tobacco: Never Used				
Alcohol Use	Drinks/Week	oz/Week		Comments
Yes				1/week
Sex Assigned at Birth	Date Recorded			
Female	10/12/2020 1:33 PM MDT			
COVID-19 Exposure	Response		Date Recorded	
In the last 14 days, have you had close contact (more than 15 minutes at a distance of six feet or less) with someone who is confirmed or suspected to have Coronavirus / COVID-19? documented as of this encounter	No / Unsure		3/15/2021 1:55 PM MDT	

BARNARD, CHRISTINE (id #2015, dob: 08/17/1954)

Medications at Time of Discharge

Medication	Sig	Dispensed	Refills	Start Date	End Date
brigatinib (ALUNBRIG) 30 mg tablet	Take 4 tablets by mouth daily for ALK+ Non-Small Cell Lung Cancer. Take with or without food. Swallow whole. Do NOT crush or chew tablets.	120 tablet	11	10/07/2020	
cholecalciferol (VITAMIN D3) 1,000 unit tablet	Take 1,000 Units by mouth daily for Osteoporosis.		0		
denosumab (PROLIA) 60 mg/mL Syrg syringe injection	Inject 60 mg into the skin every 6 months for Post-Menopausal Osteoporosis.		0		
omeprazole (PRILOSEC) 20 mg capsule	Take 20 mg by mouth every morning (before breakfast) for Heartburn.		0		

documented as of this encounter

Plan of Treatment

Not on file

documented as of this encounter

Procedures

Procedure Name	Priority	Date/Time	Associated Diagnosis	Comments
MR BRAIN W/WO CONTRAST	RAD - OP4: All Other Outpatients	03/15/2021 9:53 AM MDT	Adenocarcinoma of lung, stage 4, unspecified laterality (HC code)	Results for this procedure are in the results section.

documented in this encounter

Results

- MR BRAIN W/WO CONTRAST (03/15/2021 9:53 AM MDT):
Specimen

Impressions	Performed At
IMPRESSION: No intracranial metastases.	POWERSCRIBE

If you are a health care provider and have any questions regarding this or any other neuroradiology report please call: (720) 848-3432. The neuroradiology reading area location is B.325 AIP 2. We are staffed 8 am to 5 pm, Monday through Friday.

If you are a patient and have questions about your report please contact your health care provider.

Report E-Signed By: Andrew Callen, MD, MD at 3/15/2021 2:22 PM

WSN:PACSR64680

Narrative	Performed At
-----------	--------------

BARNARD, CHRISTINE (id #2015, dob: 08/17/1954)

MR BRAIN W/WO CONTRAST - 03/15/2021, 0953.

POWERSCRIBE

HISTORY: Non-small cell lung cancer, metastatic, assess treatment response.

Was there a contrast reaction? No

Was there a contrast or saline extravasation? No.

TECHNIQUE: Multisequence and multiplanar MRI of the brain acquired prior to and following intravenous administration of 12 ml Multihance. A Imaging was performed at 1.5 Tesla.

COMPARISON: MRI brain, 1/15/2020

FINDINGS:

Parenchyma:

Minimal T2 hyperintense white matter lesions. No acute infarct. No parenchymal mass lesion. No abnormal parenchymal enhancement.

Extra-axial spaces:

No extra-axial hemorrhage, collections, or adverse intracranial mass effect. A No abnormal meningeal enhancement.

Volume:

Parenchymal volume is normal. No hydrocephalus.

Calvarium: A

Normal

Extra-cranial:

Orbits unremarkable. The visualized paranasal sinuses are clear. No mastoid or middle ear effusions.

Procedure Note

BARNARD, CHRISTINE (id #2015, dob: 08/17/1954)

Edi, Rad Results In - 03/15/2021 2:24 PM MDT

MR BRAIN W/WO CONTRAST - 03/15/2021, 0953.

HISTORY: Non-small cell lung cancer, metastatic, assess treatment response.

Was there a contrast reaction? No

Was there a contrast or saline extravasation? No.

TECHNIQUE: Multisequence and multiplanar MRI of the brain acquired prior to and following intravenous administration of 12 ml Multihance. Imaging was performed at 1.5 Tesla.

COMPARISON: MRI brain, 1/15/2020

FINDINGS:

Parenchyma:

Minimal T2 hyperintense white matter lesions. No acute infarct. No parenchymal mass lesion. No abnormal parenchymal enhancement.

Extra-axial spaces:

No extra-axial hemorrhage, collections, or adverse intracranial mass effect. No abnormal meningeal enhancement.

Volume:

Parenchymal volume is normal. No hydrocephalus.

Calvarium:

Normal

Extra-cranial:

Orbits unremarkable. The visualized paranasal sinuses are clear. No mastoid or middle ear effusions.

IMPRESSION:

No intracranial metastases.

If you are a health care provider and have any questions regarding this or any other neuroradiology report please call: (720) 848-3432. The neuroradiology reading area location is B.325 AIP 2. We are staffed 8 am to 5 pm, Monday through Friday.

If you are a patient and have questions about your report please contact your health care provider.

Report E-Signed By: Andrew Callen, MD, MD at 3/15/2021 2:22 PM

WSN:PACSR64680

Performing Organization	Address	City/State/ZIP Code	Phone Number
POWERSCRIBE			720-848-1235

documented in this encounter

Visit Diagnoses

Diagnosis

Adenocarcinoma of lung, stage 4, unspecified laterality (HC code)

documented in this encounter

BARNARD, CHRISTINE (id #2015, dob: 08/17/1954)

Administered Medications

Inactive Administered Medications - up to 3 most recent administrations

Medication Order	MAR Action	Action Date	Dose	Rate	Site
gadobenate dimeglumine (MULTIHANCE) injection 15 mL	Given	03/15/2021 9:33 AM MDT	12 mLs		Left Arm
15 mL, Intravenous, ONCE, Mon 3/15/21 at 0930, For 1 dose, MRI Contrast					

documented in this encounter

Additional Health Concerns

Assessment	Noted Time
PHQ-2 Depression Total Score: 0	12/16/2020 8:31 AM MST
documented as of this encounter	

Demographics

Sex:	Female	Ethnicity:	Not Hispanic or Latino
DOB:	08/17/1954	Race:	White
Preferred language:	English	Marital status:	Married
Contact:	4401 MARIGOLD LANE, LITTLETON, CO 80123, USA, Ph. tel:+1-720-480-7411		

Care Team Members

Primary Care Provider	
Cara H Dawson, MD	Ph. tel:+1-720-320-2061

Radiology - Hospital Encounter - UCHealth - 03/18/2021

Encounter Summary for Christine Barnard

Most Recent Encounter

Hrh Ct 1: University of Co HealthCO

Reason for Referral

• MRI/CAT Scan (Routine):					
Status	Reason	Specialty	Diagnoses / Procedures	Referred By Contact	Referred To Contact
Closed			Diagnoses	Hall, Francis Killian, MD	
			Adenocarcinoma of lung, stage 4, unspecified laterality (HC code)	12605 E 16th Ave Aurora, CO 80014	
			Procedures	Phone: 720-848-0000	
			CT CHEST/ABD W CONTRAST	Fax: 720-718-0995	

BARNARD, CHRISTINE (id #2015, dob: 08/17/1954)

Reason for Visit

- MRI/CAT Scan (Routine):

Status	Reason	Specialty	Diagnoses / Procedures	Referred By Contact	Referred To Contact
Closed			Diagnoses Adenocarcinoma of lung, stage 4, unspecified laterality (HC code)	Hall, Francis Killian, MD 12605 E 16th Ave Aurora, CO 80014 Phone: 720-848-0000	
			Procedures CT CHEST/ABD W CONTRAST	Fax: 720-718-0995	

Encounter Details

Date	Type	Department	Care Team	Description
03/15/2021	Hospital Encounter	UCHealth Radiology - Highlands Ranch Hospital 1500 Park Central Drive Highlands Ranch, CO 80129 720-516-1002		Adenocarcinoma of lung, stage 4, unspecified laterality (HC code)

Social History

Tobacco Use	Types	Packs/Day	Years Used	Date
Never Smoker				
Smokeless Tobacco: Never Used				
Alcohol Use	Drinks/Week	oz/Week		Comments
Yes				1/week
Sex Assigned at Birth	Date Recorded			
Female	10/12/2020 1:33 PM MDT			
COVID-19 Exposure	Response		Date Recorded	
In the last 14 days, have you had close contact (more than 15 minutes at a distance of six feet or less) with someone who is confirmed or suspected to have Coronavirus / COVID-19? documented as of this encounter	No / Unsure		3/15/2021 1:55 PM MDT	

BARNARD, CHRISTINE (id #2015, dob: 08/17/1954)

Medications at Time of Discharge

Medication	Sig	Dispensed	Refills	Start Date	End Date
brigatinib (ALUNBRIG) 30 mg tablet	Take 4 tablets by mouth daily for ALK+ Non-Small Cell Lung Cancer. Take with or without food. Swallow whole. Do NOT crush or chew tablets.	120 tablet	11	10/07/2020	
cholecalciferol (VITAMIN D3) 1,000 unit tablet	Take 1,000 Units by mouth daily for Osteoporosis.		0		
denosumab (PROLIA) 60 mg/mL Syrg syringe injection	Inject 60 mg into the skin every 6 months for Post-Menopausal Osteoporosis.		0		
omeprazole (PRILOSEC) 20 mg capsule	Take 20 mg by mouth every morning (before breakfast) for Heartburn.		0		

documented as of this encounter

Plan of Treatment

Not on file

documented as of this encounter

Procedures

Procedure Name	Priority	Date/Time	Associated Diagnosis	Comments
CT CHEST/ABD W CONTRAST	RAD - OP4: All Other Outpatients	03/15/2021 8:59 AM MDT	Adenocarcinoma of lung, stage 4, unspecified laterality (HC code)	Results for this procedure are in the results section.

documented in this encounter

Results

- CT CHEST/ABD W CONTRAST (03/15/2021 8:59 AM MDT):
Specimen

Impressions

IMPRESSION: Stable postoperative changes in the superior segment of the left lower lobe. A Stable scarring and nodule at the left lung base.

CONTACT INFORMATION: If you are a health care provider and have any questions regarding this or any other Thoracic Radiology report please call 720-848-7129. The Thoracic Radiology reading area location is B.325 AIP2 basement. We are staffed 7:00 AM-5:00 PM Monday through Friday.

If you are a patient and have questions about your report please contact the health care provider who ordered this examination.

Report E-Signed By: Charles De Pena at 3/15/2021 9:54 AM

WSN:PACSR73174

Narrative

Performed At

POWERSCRIBE

Performed At

BARNARD, CHRISTINE (id #2015, dob: 08/17/1954)

POWERSCRIBE

EXAMINATION: CT CHEST ABDOMEN WITH

DATE OF EXAM: 03/15/2021, 0859

INDICATION: Non-small cell lung cancer, metastatic, assess treatment response

Was there a contrast reaction? No

Was there a contrast or saline extravasation? No

TECHNIQUE: Contiguous transverse axial CT images of the chest and abdomen were obtained, following the intravenous administration of an iodine contrast agent. Coronal and sagittal reformat images were also submitted.

A A A CONTRAST: Isovue 370 82 mL

COMPARISON: CT examination 12/14/2020, 10/12/2020 and 7/13/2020

FINDINGS:

CHEST:

Thyroid: Stable 10 mm hypoattenuating nodule in the right thyroid lobe. A

Thoracic inlet: No supraclavicular adenopathy

Mediastinum and hila: Stable left paratracheal lymph node

Heart and great vessels: Normal

Lungs, airway and pleura: Central airways patent. A Stable postsurgical changes in the left lower lobe. A Stable linear scarring and nodule (6/245) left lung base.

Breast and axilla: Normal

ABDOMEN:

Liver: No focal lesions. A Patent hepatic and portal veins

Bile ducts: No evidence of biliary ductal dilatation

Gallbladder: No calculi or pericholecystic fluid

Pancreas: Normal A

Spleen: Normal size. A Stable peripheral well-circumscribed focus of decreased attenuation

Adrenals: Normal

Kidneys, ureters: The kidneys show no evidence for mass. A There is mild pelvicalyceal prominence which is unchanged from previous examinations.

Gastrointestinal tract: Stable hemostatic clip at the lesser curvature. A Stable air in the distal esophagus.

Mesentery: Normal

Peritoneum: Negative

Retroperitoneum: No adenopathy

Vasculature: Normal

BONES AND SOFT TISSUE: Negative

Procedure Note

Edi, Rad Results In - 03/15/2021 10:10 AM MDT

BARNARD, CHRISTINE (id #2015, dob: 08/17/1954)

EXAMINATION: CT CHEST ABDOMEN WITH

DATE OF EXAM: 03/15/2021, 0859

INDICATION: Non-small cell lung cancer, metastatic, assess treatment response

Was there a contrast reaction? No

Was there a contrast or saline extravasation? No

TECHNIQUE: Contiguous transverse axial CT images of the chest and abdomen were obtained, following the intravenous administration of an iodine contrast agent. Coronal and sagittal reformat images were also submitted.

CONTRAST: Isovue 370 82 mL

COMPARISON: CT examination 12/14/2020, 10/12/2020 and 7/13/2020

FINDINGS:

CHEST:

Thyroid: Stable 10 mm hypoattenuating nodule in the right thyroid lobe.

Thoracic inlet: No supraclavicular adenopathy

Mediastinum and hila: Stable left paratracheal lymph node

Heart and great vessels: Normal

Lungs, airway and pleura: Central airways patent. Stable postsurgical changes in the left lower lobe. Stable linear scarring and nodule (6/245) left lung base.

Breast and axilla: Normal

ABDOMEN:

Liver: No focal lesions. Patent hepatic and portal veins

Bile ducts: No evidence of biliary ductal dilatation

Gallbladder: No calculi or pericholecystic fluid

Pancreas: Normal

Spleen: Normal size. Stable peripheral well-circumscribed focus of decreased attenuation

Adrenals: Normal

Kidneys, ureters: The kidneys show no evidence for mass. There is mild pelvicalyceal prominence which is unchanged from previous examinations.

Gastrointestinal tract: Stable hemostatic clip at the lesser curvature. Stable air in the distal esophagus.

Mesentery: Normal

Peritoneum: Negative

Retroperitoneum: No adenopathy

Vasculature: Normal

BONES AND SOFT TISSUE: Negative

IMPRESSION: Stable postoperative changes in the superior segment of the left lower lobe. Stable scarring and nodule at the left lung base.

BARNARD, CHRISTINE (id #2015, dob: 08/17/1954)

CONTACT INFORMATION: If you are a health care provider and have any questions regarding this or any other Thoracic Radiology report please call 720-848-7129. The Thoracic Radiology reading area location is B.325 AIP2 basement. We are staffed 7:00 AM-5:00 PM Monday through Friday.

If you are a patient and have questions about your report please contact the health care provider who ordered this examination.

Report E-Signed By: Charles De Pena at 3/15/2021 9:54 AM
WSN:PACSR73174

Performing Organization	Address	City/State/ZIP Code	Phone Number
POWERSCRIBE			720-848-1235

documented in this encounter

Visit Diagnoses

Diagnosis

Adenocarcinoma of lung, stage 4, unspecified laterality (HC code)
documented in this encounter

Administered Medications

Inactive Administered Medications - up to 3 most recent administrations

Medication Order	MAR Action	Action Date	Dose	Rate	Site
iopamidoL (ISOVUE-370) 76 % injection 82 mL	Given	03/15/2021 9:30 AM MDT	82 mLs		
82 mL, Intravenous, ONCE, Mon 3/15/21 at 0930, For 1 dose, CT Contrast					

documented in this encounter

Additional Health Concerns

Assessment	Noted Time
PHQ-2 Depression Total Score: 0	12/16/2020 8:31 AM MST
documented as of this encounter	

Demographics

Sex:	Female	Ethnicity:	Not Hispanic or Latino
DOB:	08/17/1954	Race:	White
Preferred language:	English	Marital status:	Married
Contact:	4401 MARIGOLD LANE, LITTLETON, CO 80123, USA, Ph. tel:+1-720-480-7411		

Care Team Members

Primary Care Provider	
Cara H Dawson, MD	Ph. tel:+1-720-320-2061

General Medicine - Continuity of Care Document - UCHealth - 03/18/2021

Clinical Summary for Christine Barnard

Allergies

Active Allergy	Reactions	Severity	Noted Date	Comments
Codeine				NAUSEA VOMITING
Sulfa (Sulfonamide Antibiotics)	Hives, Itching, Rash	High	01/31/2017	

BARNARD, CHRISTINE (id #2015, dob: 08/17/1954)

Medications

Medication	Sig	Dispensed	Refills	Start Date	End Date	Status
denosumab (PROLIA) 60 mg/mL Syrg syringe injection	Inject 60 mg into the skin every 6 months for Post-Menopausal Osteoporosis.		0			Active
cholecalciferol (VITAMIN D3) 1,000 unit tablet	Take 1,000 Units by mouth daily for Osteoporosis.		0			Active
omeprazole (PRILOSEC) 20 mg capsule	Take 20 mg by mouth every morning (before breakfast) for Heartburn.		0			Active
brigatinib (ALUNBRIG) 30 mg tablet	Take 4 tablets by mouth daily for ALK+ Non-Small Cell Lung Cancer. Take with or without food. Swallow whole. Do NOT crush or chew tablets.	120 tablet	11	10/07/2020		Active

Active Problems

Problem	Noted Date
Adenocarcinoma of lung, stage 4	02/02/2017
Non-small cell carcinoma of left lung, stage 4	01/31/2017

Overview:

Stage IVA NSCLC, first Dx in 01/16/17, presenting with left lower chest wall pain.

Disease sites at dx: A LUL, LLL, pleura

Histology: superior LUL wedge (well diff adenoca, acinar); sup LLL wedge (well diff adenoca, acinar; diffuse pleural nodularity); pleural biopsy (well diff adenoca) -- TTF-1 and Napsin A+; CK7+; CK20(-)

Operative report (01/16/17): A nodularity noted visceral and parietal pleural surface and diaphragm, nodules in superior LUL and sup LLL/periarota (not invading into aorta)

Molecular status: A ALK FISH+ (01/16/17). Negative for EGFR exon 19-21 / KRAS / ROS-1

First line Rx: A Ariad ALTA 16-0006 Crizotinib arm from 02/09/2017 to present with CR to Rx

Complicated by esophageal candidiasis in Aug 2017 -- treated with Fluconazole x 3 weeks. Recurrence of dysphagia and globus sensation in Nov 2017 -- restarted Fluconazole from 11/10/17 to 12/07/2017. EGD (11/17/2017) normal, no evidence of candidiasis and has completely resolved. Rising tumor markers noticeable since 01/10/2018, and came off study and discontinued crizotinib on 02/14/2018 due to PD (left pleural effusion + thickening in LLL resection scar)

Second line Rx: Brigatinib 90 mg daily from 02/28/2018 to 03/06/2018, then 180 mg daily 03/07/2018 to present with PR to Rx

Current disease sites: A pleura (LUL major fissure and medial LLL nodule resected). No intracranial metastases at baseline or with current imaging.

BARNARD, CHRISTINE (id #2015, dob: 08/17/1954)

Encounters

Date	Type	Specialty	Care Team	Description
03/17/2021	Office Visit	Hematology and Oncology	Camidge, David Ross, MD PhD	Non-small cell carcinoma of left lung, stage 4 (HC code) (Primary Dx)
03/16/2021	Orders Only	Hematology and Oncology	Camidge, David Ross, MD PhD	
03/15/2021	Hospital Encounter	Radiology		Adenocarcinoma of lung, stage 4, unspecified laterality (HC code)
03/15/2021	Hospital Encounter	Radiology		Adenocarcinoma of lung, stage 4, unspecified laterality (HC code)
03/15/2021	Lab Only	Lab		Adenocarcinoma of lung, stage 4, unspecified laterality (HC code)
03/12/2021	Orders Only	Hematology and Oncology	Rounsborg, Dana, RN	
03/08/2021	Immunization	Family Medicine		
03/08/2021	Orders Only	Hematology and Oncology	Miller, Ronni Matheke, PharmD	Adenocarcinoma of lung, stage 4, unspecified laterality (HC code) (Primary Dx)
02/15/2021	Immunization from Last 3 Months	Family Medicine		

Immunizations

Name	Administration Dates	Next Due
IPV (Inactivated Poliovirus)	11/15/2017, 10/10/2017	
Influenza, Fluvirin/Fluzone	10/05/2018	
PFIZER, SARS-COV2 (COVID-19) VACCINE	03/08/2021, 02/15/2021	
influenza, injectable, quadrivalent, preservative free	10/10/2017	

Family History

Medical History	Relation	Name	Comments
Heart attack	Brother		
Heart attack	Brother		
Melanoma	Father		
Diabetes	Mother		
Heart failure	Mother		
Stroke	Mother		
Relation	Name	Status	Comments
Brother			
Brother			
Father			
Mother			

BARNARD, CHRISTINE (id #2015, dob: 08/17/1954)

Social History

Tobacco Use	Types	Packs/Day	Years Used	Date
Never Smoker				
Smokeless Tobacco: Never Used				
Alcohol Use	Drinks/Week	oz/Week	Comments	
Yes			1/week	
Sex Assigned at Birth	Date Recorded			
Female	10/12/2020 1:33 PM MDT			
COVID-19 Exposure	Response		Date Recorded	
In the last 14 days, have you had close contact (more than 15 minutes at a distance of six feet or less) with someone who is confirmed or suspected to have Coronavirus / COVID-19?	No / Unsure		3/17/2021 8:50 AM MDT	

Last Filed Vital Signs

Vital Sign	Reading	Time Taken	Comments
Blood Pressure	121/80	03/17/2021 8:54 AM MDT	
Pulse	80	03/17/2021 8:54 AM MDT	
Temperature	35.2 A?C (95.4 A?F)	03/17/2021 8:54 AM MDT	
Respiratory Rate	16	03/17/2021 8:54 AM MDT	
Oxygen Saturation	96%	03/17/2021 8:54 AM MDT	
Inhaled Oxygen Concentration	-	-	
Weight	57.2 kg (126 lb)	03/17/2021 8:55 AM MDT	
Height	163.8 cm (5' 4.5")	03/17/2021 8:55 AM MDT	
Body Mass Index	21.29	03/17/2021 8:55 AM MDT	

Plan of Treatment

Health Maintenance	Due Date	Last Done	Comments
Dexa Scan Screening	08/17/1954		
Lipids	08/17/1964		
Mammography	08/17/1964		
Colon Cancer Screening CT Colonography	08/17/2004		
Colon Cancer Screening FIT 1 Year	08/17/2004		
Colon Cancer Screening FOBT	08/17/2004		
Colon Cancer Screening Flex Sig	08/17/2004		
Colon Cancer Screening Stool DNA Test	08/17/2004		
Colon Cancer Screening Colonoscopy	08/17/2004		
Hep C Antibody	08/17/2004		
Zoster Vaccines (2 of 2)	03/04/2021	01/07/2021	
Influenza Vaccine	Completed	09/21/2020, 10/16/2019, 10/07/2018, Additional history exists	
Pneumonia Vaccine	Completed	12/10/2020, 10/16/2019	
SARS-COV2 (COVID-19) Vaccine	Completed	03/08/2021, 02/15/2021	
PAP Not Applicable	Discontinued		

BARNARD, CHRISTINE (id #2015, dob: 08/17/1954)

Procedures

Procedure Name	Priority	Date/Time	Associated Diagnosis	Comments
MR BRAIN W/WO CONTRAST	RAD - OP4: All Other Outpatients	03/15/2021 9:53 AM MDT	Adenocarcinoma of lung, stage 4, unspecified laterality (HC code)	Results for this procedure are in the results section.
CT CHEST/ABD W CONTRAST	RAD - OP4: All Other Outpatients	03/15/2021 8:59 AM MDT	Adenocarcinoma of lung, stage 4, unspecified laterality (HC code)	Results for this procedure are in the results section.
LIPASE	STAT	03/15/2021 8:10 AM MDT	Adenocarcinoma of lung, stage 4, unspecified laterality (HC code)	Results for this procedure are in the results section.
AMYLASE SERUM	STAT	03/15/2021 8:10 AM MDT	Adenocarcinoma of lung, stage 4, unspecified laterality (HC code)	Results for this procedure are in the results section.
CREATINE KINASE	STAT	03/15/2021 8:10 AM MDT	Adenocarcinoma of lung, stage 4, unspecified laterality (HC code)	Results for this procedure are in the results section.
COMPREHENSIVE METABOLIC PANEL	STAT	03/15/2021 8:10 AM MDT	Adenocarcinoma of lung, stage 4, unspecified laterality (HC code)	Results for this procedure are in the results section.
CBC, ONCOLOGY	STAT	03/15/2021 8:10 AM MDT	Adenocarcinoma of lung, stage 4, unspecified laterality (HC code)	Results for this procedure are in the results section.
CANCER ANTIGEN 125	Routine	03/15/2021 8:10 AM MDT	Adenocarcinoma of lung, stage 4, unspecified laterality (HC code)	Results for this procedure are in the results section.
CARCINOEMBRYONIC ANTIGEN	Routine	03/15/2021 8:10 AM MDT	Adenocarcinoma of lung, stage 4, unspecified laterality (HC code)	Results for this procedure are in the results section.

from Last 3 Months

Results

- MR BRAIN W/WO CONTRAST (03/15/2021 9:53 AM MDT):
Specimen

Impressions

IMPRESSION:

No intracranial metastases.

Performed At

POWERSCRIBE

If you are a health care provider and have any questions regarding this or any other neuroradiology report please call: (720) 848-3432. The neuroradiology reading area location is B.325 AIP 2. We are staffed 8 am to 5 pm, Monday through Friday.

If you are a patient and have questions about your report please contact your health care provider.

Report E-Signed By: Andrew Callen, MD, MD at 3/15/2021 2:22 PM

WSN:PACSR64680

Narrative

Performed At

BARNARD, CHRISTINE (id #2015, dob: 08/17/1954)

MR BRAIN W/WO CONTRAST - 03/15/2021, 0953.

POWERSCRIBE

HISTORY: Non-small cell lung cancer, metastatic, assess treatment response.

Was there a contrast reaction? No

Was there a contrast or saline extravasation? No.

TECHNIQUE: Multisequence and multiplanar MRI of the brain acquired prior to and following intravenous administration of 12 ml Multihance. A Imaging was performed at 1.5 Tesla.

COMPARISON: MRI brain, 1/15/2020

FINDINGS:

Parenchyma:

Minimal T2 hyperintense white matter lesions. No acute infarct. No parenchymal mass lesion. No abnormal parenchymal enhancement.

Extra-axial spaces:

No extra-axial hemorrhage, collections, or adverse intracranial mass effect. A No abnormal meningeal enhancement.

Volume:

Parenchymal volume is normal. No hydrocephalus.

Calvarium: A

Normal

Extra-cranial:

Orbits unremarkable. The visualized paranasal sinuses are clear. No mastoid or middle ear effusions.

Procedure Note

BARNARD, CHRISTINE (id #2015, dob: 08/17/1954)

Edi, Rad Results In - 03/15/2021 2:24 PM MDT

MR BRAIN W/WO CONTRAST - 03/15/2021, 0953.

HISTORY: Non-small cell lung cancer, metastatic, assess treatment response.

Was there a contrast reaction? No

Was there a contrast or saline extravasation? No.

TECHNIQUE: Multisequence and multiplanar MRI of the brain acquired prior to and following intravenous administration of 12 ml Multihance. Imaging was performed at 1.5 Tesla.

COMPARISON: MRI brain, 1/15/2020

FINDINGS:

Parenchyma:

Minimal T2 hyperintense white matter lesions. No acute infarct. No parenchymal mass lesion. No abnormal parenchymal enhancement.

Extra-axial spaces:

No extra-axial hemorrhage, collections, or adverse intracranial mass effect. No abnormal meningeal enhancement.

Volume:

Parenchymal volume is normal. No hydrocephalus.

Calvarium:

Normal

Extra-cranial:

Orbits unremarkable. The visualized paranasal sinuses are clear. No mastoid or middle ear effusions.

IMPRESSION:

No intracranial metastases.

If you are a health care provider and have any questions regarding this or any other neuroradiology report please call: (720) 848-3432. The neuroradiology reading area location is B.325 AIP 2. We are staffed 8 am to 5 pm, Monday through Friday.

If you are a patient and have questions about your report please contact your health care provider.

Report E-Signed By: Andrew Callen, MD, MD at 3/15/2021 2:22 PM

WSN:PACSR64680

Performing Organization	Address	City/State/ZIP Code	Phone Number
POWERSCRIBE			720-848-1235

- CT CHEST/ABD W CONTRAST (03/15/2021 8:59 AM MDT):
Specimen

Impressions	Performed At
IMPRESSION: Stable postoperative changes in the superior segment of the left lower lobe. A Stable scarring and nodule at the left lung base.	POWERSCRIBE

CONTACT INFORMATION: If you are a health care provider and have any questions regarding this or any other Thoracic Radiology report please call 720-848-7129. The Thoracic Radiology reading area location is B.325 AIP2 basement. We are staffed 7:00 AM-5:00 PM Monday through Friday.

If you are a patient and have questions about your report please contact the health care provider who ordered this examination.

Report E-Signed By: Charles De Pena at 3/15/2021 9:54 AM

WSN:PACSR73174

Narrative	Performed At
-----------	--------------

BARNARD, CHRISTINE (id #2015, dob: 08/17/1954)

EXAMINATION: CT CHEST ABDOMEN WITH

POWERSCRIBE

DATE OF EXAM: 03/15/2021, 0859

INDICATION: Non-small cell lung cancer, metastatic, assess treatment response

Was there a contrast reaction? No

Was there a contrast or saline extravasation? No

TECHNIQUE: Contiguous transverse axial CT images of the chest and abdomen were obtained, following the intravenous administration of an iodine contrast agent. Coronal and sagittal reformat images were also submitted.

A A A CONTRAST: Isovue 370 82 mL

COMPARISON: CT examination 12/14/2020, 10/12/2020 and 7/13/2020

FINDINGS:

CHEST:

Thyroid: Stable 10 mm hypoattenuating nodule in the right thyroid lobe. A

Thoracic inlet: No supraclavicular adenopathy

Mediastinum and hila: Stable left paratracheal lymph node

Heart and great vessels: Normal

Lungs, airway and pleura: Central airways patent. A Stable postsurgical changes in the left lower lobe. A Stable linear scarring and nodule (6/245) left lung base.

Breast and axilla: Normal

ABDOMEN:

Liver: No focal lesions. A Patent hepatic and portal veins

Bile ducts: No evidence of biliary ductal dilatation

Gallbladder: No calculi or pericholecystic fluid

Pancreas: Normal A

Spleen: Normal size. A Stable peripheral well-circumscribed focus of decreased attenuation

Adrenals: Normal

Kidneys, ureters: The kidneys show no evidence for mass. A There is mild pelvicalyceal prominence which is unchanged from previous examinations.

Gastrointestinal tract: Stable hemostatic clip at the lesser curvature. A Stable air in the distal esophagus.

Mesentery: Normal

Peritoneum: Negative

Retroperitoneum: No adenopathy

Vasculature: Normal

BONES AND SOFT TISSUE: Negative

Procedure Note

Edi, Rad Results In - 03/15/2021 10:10 AM MDT

BARNARD, CHRISTINE (id #2015, dob: 08/17/1954)

EXAMINATION: CT CHEST ABDOMEN WITH

DATE OF EXAM: 03/15/2021, 0859

INDICATION: Non-small cell lung cancer, metastatic, assess treatment response

Was there a contrast reaction? No

Was there a contrast or saline extravasation? No

TECHNIQUE: Contiguous transverse axial CT images of the chest and abdomen were obtained, following the intravenous administration of an iodine contrast agent. Coronal and sagittal reformat images were also submitted.

CONTRAST: Isovue 370 82 mL

COMPARISON: CT examination 12/14/2020, 10/12/2020 and 7/13/2020

FINDINGS:

CHEST:

Thyroid: Stable 10 mm hypoattenuating nodule in the right thyroid lobe.

Thoracic inlet: No supraclavicular adenopathy

Mediastinum and hila: Stable left paratracheal lymph node

Heart and great vessels: Normal

Lungs, airway and pleura: Central airways patent. Stable postsurgical changes in the left lower lobe. Stable linear scarring and nodule (6/245) left lung base.

Breast and axilla: Normal

ABDOMEN:

Liver: No focal lesions. Patent hepatic and portal veins

Bile ducts: No evidence of biliary ductal dilatation

Gallbladder: No calculi or pericholecystic fluid

Pancreas: Normal

Spleen: Normal size. Stable peripheral well-circumscribed focus of decreased attenuation

Adrenals: Normal

Kidneys, ureters: The kidneys show no evidence for mass. There is mild pelvicalyceal prominence which is unchanged from previous examinations.

Gastrointestinal tract: Stable hemostatic clip at the lesser curvature. Stable air in the distal esophagus.

Mesentery: Normal

Peritoneum: Negative

Retroperitoneum: No adenopathy

Vasculature: Normal

BONES AND SOFT TISSUE: Negative

IMPRESSION: Stable postoperative changes in the superior segment of the left lower lobe. Stable scarring and nodule at the left lung base.

BARNARD, CHRISTINE (id #2015, dob: 08/17/1954)

CONTACT INFORMATION: If you are a health care provider and have any questions regarding this or any other Thoracic Radiology report please call 720-848-7129. The Thoracic Radiology reading area location is B.325 AIP2 basement. We are staffed 7:00 AM-5:00 PM Monday through Friday.

If you are a patient and have questions about your report please contact the health care provider who ordered this examination.

Report E-Signed By: Charles De Pena at 3/15/2021 9:54 AM

WSN:PACSR73174

Performing Organization	Address	City/State/ZIP Code	Phone Number
POWERSCRIBE			720-848-1235

• CBC Oncology (03/15/2021 8:10 AM MDT):

Component	Value	Ref Range	Performed At	Pathologist Signature
White Blood Cell Count	4.9	4.0 - 11.1 10 ⁹ /L	HRH HOSPITAL LAB	
Red Blood Cell Count	4.48	4.18 - 5.64 10 ¹² /L	HRH HOSPITAL LAB	
Hemoglobin	13.0	12.1 - 16.3 g/dL	HRH HOSPITAL LAB	
Hematocrit	40.3	35.7 - 46.7 %	HRH HOSPITAL LAB	
Mean Corpuscular Volume	90.0	80.0 - 100.0 fL	HRH HOSPITAL LAB	
Mean Corpuscular Hemoglobin	29.0	27.5 - 35.1 pg	HRH HOSPITAL LAB	
Mean Corpuscular Hemoglobin Concentration	32.3	32.0 - 36.0 g/dL	HRH HOSPITAL LAB	
Platelet Count	206	150 - 400 10 ⁹ /L	HRH HOSPITAL LAB	
Red Cell Distribution Width CV	14.2	11.7 - 14.2 %	HRH HOSPITAL LAB	
NRBC Percent	0.0	0 %	HRH HOSPITAL LAB	
NRBC Absolute	0.00	0 - 0.1 10 ⁹ /L	HRH HOSPITAL LAB	
Segmented Neutrophil Percent	49.5	%	HRH HOSPITAL LAB	
Lymphocyte Percent	37.9	%	HRH HOSPITAL LAB	
Monocytes Percent	9.2	%	HRH HOSPITAL LAB	
Eosinophils Percent	2.2	%	HRH HOSPITAL LAB	
Basophils Percent	0.8	%	HRH HOSPITAL LAB	

BARNARD, CHRISTINE (id #2015, dob: 08/17/1954)

Immature Granulocytes Percent	0.4	%	HRH HOSPITAL LAB
Neutrophils Absolute	2.4	1.8 - 6.6 10 ⁹ /L	HRH HOSPITAL LAB
Lymphocyte Absolute	1.9	1.0 - 4.8 10 ⁹ /L	HRH HOSPITAL LAB
Monocytes Absolute	0.5	0.2 - 0.9 10 ⁹ /L	HRH HOSPITAL LAB
Eosinophils Absolute	0.1	0.0 - 0.4 10 ⁹ /L	HRH HOSPITAL LAB
Basophils Absolute	0.0	0.0 - 0.2 10 ⁹ /L	HRH HOSPITAL LAB
Immature Granulocytes Absolute	0.0	0.0 - 0.1 10 ⁹ /L	HRH HOSPITAL LAB

Specimen

Blood - Blood specimen (specimen)

Performing Organization	Address	City/State/ZIP Code	Phone Number
HRH HOSPITAL LAB	1500 PARK CENTRAL DRIVE	HIGHLANDS RANCH, CO 80129	

- Cancer Antigen 125 (03/15/2021 8:10 AM MDT):

Component	Value	Ref Range	Performed At	Pathologist Signature
Cancer Antigen 125 DXI		0 - 35 U/mL	ANSCHUTZ MEDICAL CAMPUS LAB, AURORA, CO	

Specimen

Blood - Blood specimen (specimen)

Narrative			Performed At
Tested with Access OV Monitor Cancer Antigen 125 assay; other assays' values aren't interchangeable.			ANSCHUTZ MEDICAL CAMPUS LAB, AURORA, CO
Performing Organization	Address	City/State/ZIP Code	Phone Number
ANSCHUTZ MEDICAL CAMPUS LAB, AURORA, CO	12401 East 17th Avenue Campus Box A022	AURORA, CO 80045	720-848-4401

- Lipase (03/15/2021 8:10 AM MDT):

Component	Value	Ref Range	Performed At	Pathologist Signature
Lipase Serum/Plasma	137	23 - 300 U/L	HRH HOSPITAL LAB	

Specimen

Blood - Blood specimen (specimen)

Performing Organization	Address	City/State/ZIP Code	Phone Number
HRH HOSPITAL LAB	1500 PARK CENTRAL DRIVE	HIGHLANDS RANCH, CO 80129	

- Creatinine Kinase (03/15/2021 8:10 AM MDT):

Component	Value	Ref Range	Performed At	Pathologist Signature
Creatine Kinase	606 (H)	30 - 223 U/L	HRH HOSPITAL LAB	

Specimen

Blood - Blood specimen (specimen)

Performing Organization	Address	City/State/ZIP Code	Phone Number
HRH HOSPITAL LAB	1500 PARK CENTRAL DRIVE	HIGHLANDS RANCH, CO 80129	

- Carcinoembryonic Antigen (03/15/2021 8:10 AM MDT):

BARNARD, CHRISTINE (id #2015, dob: 08/17/1954)

Component	Value	Ref Range	Performed At	Pathologist Signature
Carcinoembryonic Antigen ORTHO	2.2	<=5.0 ng/mL	HRH HOSPITAL LAB	

Specimen

Blood - Blood specimen (specimen)

Performing Organization	Address	City/State/ZIP Code	Phone Number
HRH HOSPITAL LAB	1500 PARK CENTRAL DRIVE	HIGHLANDS RANCH, CO 80129	

- Amylase serum (03/15/2021 8:10 AM MDT):

Component	Value	Ref Range	Performed At	Pathologist Signature
Amylase Serum	92	30 - 110 U/L	HRH HOSPITAL LAB	

Specimen

Blood - Blood specimen (specimen)

Performing Organization	Address	City/State/ZIP Code	Phone Number
HRH HOSPITAL LAB	1500 PARK CENTRAL DRIVE	HIGHLANDS RANCH, CO 80129	

- Comprehensive metabolic panel (03/15/2021 8:10 AM MDT):

Component	Value	Ref Range	Performed At	Pathologist Signature
Sodium Serum/Plasma	140	134 - 145 mmol/L	HRH HOSPITAL LAB	
Potassium Serum/Plasma	4.1	3.5 - 5.1 mmol/L	HRH HOSPITAL LAB	
Chloride Serum/Plasma	107	98 - 109 mmol/L	HRH HOSPITAL LAB	
Carbon Dioxide	25	22 - 30 mmol/L	HRH HOSPITAL LAB	
Anion Gap	8	4 - 15 mmol/L	HRH HOSPITAL LAB	
Glucose Serum/Plasma	88	70 - 199 mg/dL	HRH HOSPITAL LAB	
Blood Urea Nitrogen	20 (H)	7 - 17 mg/dL	HRH HOSPITAL LAB	
Creatinine Serum/Plasma	0.70	0.52 - 1.04 mg/dL	HRH HOSPITAL LAB	
Estimated GFR	>90Comment: The IDMS-traceable CKD-EPI equation for ages 18-97 years was used to approximate GFR. This calculation is often unreliable when someone is acutely ill or pregnant. This estimation assumes that one has an average physique and diet. If necessary, consider ordering cystatin C to further assess renal function and CKD.		>=60 mL/min/1.73 "square meters"	HRH HOSPITAL LAB

BARNARD, CHRISTINE (id #2015, dob: 08/17/1954)

Estimated GFR (incl. race term)	>90	Comment: The IDMS-traceable CKD-EPI equation for ages 18-97 years was used to approximate GFR. This calculation is often unreliable when someone is acutely ill or pregnant. This estimation assumes that one has an average physique and diet. If necessary, consider ordering cystatin C to further assess renal function and CKD.	>=60 mL/min/1.73 "square meters"	HRH HOSPITAL LAB
BUN/Creatinine Ratio	28.6			HRH HOSPITAL LAB
Calcium Serum/Plasma	9.6		8.4 - 10.2 mg/dL	HRH HOSPITAL LAB
Protein Total Serum/Plasma	7.4		6.4 - 8.9 g/dL	HRH HOSPITAL LAB
Albumin	4.5		3.5 - 5.0 g/dL	HRH HOSPITAL LAB
Bilirubin Total	0.6		0.2 - 1.3 mg/dL	HRH HOSPITAL LAB
Alkaline Phosphatase Total	97		38 - 126 U/L	HRH HOSPITAL LAB
Aspartate Aminotransferase	54		16 - 55 U/L	HRH HOSPITAL LAB
Alanine Aminotransferase	33		<35 U/L	HRH HOSPITAL LAB
Total Globulin	2.9		2.3 - 3.9 g/dL	HRH HOSPITAL LAB
A/G Ratio	1.6		Ratio	HRH HOSPITAL LAB

Specimen

Blood - Blood specimen (specimen)

Performing Organization	Address	City/State/ZIP Code	Phone Number
HRH HOSPITAL LAB	1500 PARK CENTRAL DRIVE	HIGHLANDS RANCH, CO 80129	

from Last 3 Months

Advance Directives

Documents on File

Type	Date Recorded	Patient Representative Explanation
Power of Attorney		
Advance Directive		
Advance Directive	4/12/2017 10:20 AM	Medical Durable Power of Attorney, Advance Directive for Healthcare Decisions

BARNARD, CHRISTINE (id #2015, dob: 08/17/1954)

Demographics

Sex: Female Ethnicity: Not Hispanic or Latino
DOB: 08/17/1954 Race: White
Preferred language: English Marital status: Married

Contact: 4401 MARIGOLD LANE, LITTLETON, CO 80123, USA, Ph. tel:+1-720-480-7411

Care Team Members

Primary Care Provider

Cara H Dawson, MD Ph. tel:+1-720-320-2061

Hematology and Oncology - Office Visit - David Camidge, UCHealth - 03/18/2021

Encounter Summary for Christine Barnard

Most Recent Encounter

David Ross Camidge, MD PhD: 1665 Aurora Ct, ACP, Mail Stop F704, Aurora, CO 80045, Ph. tel:+1-720-848-0300

Reason for Referral

- MRI/CAT Scan (Routine):

Status	Reason	Specialty	Diagnoses / Procedures	Referred By Contact	Referred To Contact
New Request			Diagnoses	Camidge, David Ross, MD PhD	
			Non-small cell carcinoma of left lung, stage 4 (HC code)	1665 Aurora Ct ACP, Mail Stop F704	
			Procedures	Aurora, CO 80045	
			CT CHEST/ABD W CONTRAST	Phone: 720-848-0300	
				Fax: 720-848-0360	

BARNARD, CHRISTINE (id #2015, dob: 08/17/1954)

Reason for Visit

<ul style="list-style-type: none"> Reason 					
Follow-up					
<ul style="list-style-type: none"> Consultation (Routine): 					
Status	Reason	Specialty	Diagnoses / Procedures	Referred By Contact	Referred To Contact
Authorized	Specialty Services Required	Hematology and Oncology	Diagnoses Non-small cell carcinoma of left lung, stage 4 (HC code)	Amc Onc Spec Op 1665 Aurora Court, 2nd Floor Aurora, CO 80045-2548 Phone: 720-848-9264 Fax: 720-848-0360	Amc Onc Spec Op 1665 Aurora Court, 2nd Floor Aurora, CO 80045-2548 Phone: 720-848-9264 Fax: 720-848-0360

Encounter Details

Date	Type	Department	Care Team	Description
03/17/2021	Office Visit	UCHealth University of Colorado Cancer Center - Anschutz Medical Campus 1665 Aurora Court, 2nd Floor Aurora, CO 80045-2548 720-848-9264	Camidge, David Ross, MD PhD 1665 Aurora Ct ACP, Mail Stop F704 Aurora, CO 80045 720-848-0300 720-848-0360 (Fax)	Non-small cell carcinoma of left lung, stage 4 (HC code) (Primary Dx)

Social History

Tobacco Use	Types	Packs/Day	Years Used	Date
Never Smoker				
Smokeless Tobacco: Never Used				
Alcohol Use	Drinks/Week	oz/Week	Comments	
Yes			1/week	
Sex Assigned at Birth	Date Recorded			
Female	10/12/2020 1:33 PM MDT			
COVID-19 Exposure	Response		Date Recorded	
In the last 14 days, have you had close contact (more than 15 minutes at a distance of six feet or less) with someone who is confirmed or suspected to have Coronavirus / COVID-19? documented as of this encounter	No / Unsure		3/17/2021 8:50 AM MDT	

BARNARD, CHRISTINE (id #2015, dob: 08/17/1954)

Last Filed Vital Signs

Vital Sign	Reading	Time Taken	Comments
Blood Pressure	121/80	03/17/2021 8:54 AM MDT	
Pulse	80	03/17/2021 8:54 AM MDT	
Temperature	35.2 A?C (95.4 A?F)	03/17/2021 8:54 AM MDT	
Respiratory Rate	16	03/17/2021 8:54 AM MDT	
Oxygen Saturation	96%	03/17/2021 8:54 AM MDT	
Inhaled Oxygen Concentration	-	-	
Weight	57.2 kg (126 lb)	03/17/2021 8:55 AM MDT	
Height	163.8 cm (5' 4.5")	03/17/2021 8:55 AM MDT	
Body Mass Index	21.29	03/17/2021 8:55 AM MDT	
documented in this encounter			

Plan of Treatment

Scheduled Orders

Name	Type	Priority	Associated Diagnoses	Order Schedule
CT CHEST/ABD W CONTRAST	Imaging	RAD - OP4: All Other Outpatients	Non-small cell carcinoma of left lung, stage 4 (HC code)	Expected: 06/17/2021, Expires: 03/17/2022
CBC w/Manual Diff if Auto Diff Fails	Lab	Routine	Non-small cell carcinoma of left lung, stage 4 (HC code)	Expected: 06/17/2021, Expires: 05/17/2022
Comprehensive Metabolic Panel	Lab	Routine	Non-small cell carcinoma of left lung, stage 4 (HC code)	Expected: 06/17/2021, Expires: 05/17/2022
Carcinoembryonic Antigen (CEA)	Lab	Routine	Non-small cell carcinoma of left lung, stage 4 (HC code)	Expected: 06/17/2021, Expires: 05/17/2022
Cancer Antigen 19-9 (GI)	Lab	Routine	Non-small cell carcinoma of left lung, stage 4 (HC code)	Expected: 06/17/2021, Expires: 05/17/2022
Cancer Antigen 27.29	Lab	Routine	Non-small cell carcinoma of left lung, stage 4 (HC code)	Expected: 06/17/2021, Expires: 05/17/2022
Cancer Antigen 125 (CA 125)	Lab	Routine	Non-small cell carcinoma of left lung, stage 4 (HC code)	Expected: 06/17/2021, Expires: 05/17/2022
Creatine Kinase	Lab	Routine	Non-small cell carcinoma of left lung, stage 4 (HC code)	Expected: 06/17/2021, Expires: 05/17/2022

documented as of this encounter

Visit Diagnoses

Diagnosis

Non-small cell carcinoma of left lung, stage 4 (HC code) - Primary

documented in this encounter

Additional Health Concerns

Assessment

PHQ-2 Depression Total Score: 0

documented as of this encounter

Noted Time

03/17/2021 8:55 AM MDT

Demographics

Sex:	Female	Ethnicity:	Not Hispanic or Latino
DOB:	08/17/1954	Race:	White
Preferred language:	English	Marital status:	Married

Contact: 4401 MARIGOLD LANE, LITTLETON, CO 80123, USA, Ph. tel:+1-720-480-7411

BARNARD, CHRISTINE (id #2015, dob: 08/17/1954)

Care Team Members

Primary Care Provider

Cara H Dawson, MD

Ph. tel:+1-720-320-2061

Lab Results

BARNARD, CHRISTINE (id #2015, dob: 08/17/1954)
LUNG BIOPSY, PATHOLOGY REPORT 03/18/2021 (#622839)

HEALTHONE ROSE MEDICAL CENTER
4567 E NINTH AVENUE
DENVER CO 80220

PATIENT NAME: BARNARD, CHRISTINE MARIE
ACCOUNT#:
MED REC#: AM00132890
LOCATION:

ATTENDING PHY:

PATHOLOGY REPORT

REPORT#: 0623-0148 REPORT STATUS: Signed
ROSE ADDENDUM

Specimen(s) Received:
A: Lung, left superior upper lobe, wedge biopsy
B: Lung, left superior lower lobe, wedge biopsy
C: Pleura, biopsy

Date Ordered: 6/16/2017
Interpretation
EGFR Mutation Analysis

Paraffin block used: RS17-217 A3
Specimen source: Lung upper lobe

Result: NOT DETECTED
Reference range: Not Detected

Based on Sanger sequencing analysis, no mutations were detected in EGFR exons 18, 19, 20 and 21, including Thr790Met (T790M) in exon 20. This specimen was examined under a microscope, marked by a pathologist and macro-dissected for nucleic acid extraction (manual dissection under microscopic observation). (Tumor cellularity was 60%.)

EGFR kinase domain mutations are found in 10 - 15% of lung adenocarcinomas, particularly those occurring in younger patients without a smoking history, and identify tumors that may have a significant clinical response to EGFR-targeted kinase inhibitors.

Secondary somatic mutations in EGFR, particularly T790M in exon 20, may accompany acquired resistance to these inhibitors. Newer FDA-approved agents are available for patients with the T790M mutation.

Microscopic review and marking of the specimen was performed by a pathologist, and genomic DNA was extracted from

PATIENT NAME: BARNARD, CHRISTINE MARIE ACCOUNT #:

Denver Patient Care Inquiry (PCI: OE Database COCYE)

BARNARD, CHRISTINE (id #2015, dob: 08/17/1954)

macro-dissected paraffin-embedded tissue sections. PCR-based DNA sequencing was used to assess for mutations in exons 18-21 of EGFR, which are the sites of greater than 95% of somatic mutations observed in tumors. This analysis includes the T790M mutation which is commonly associated with secondary resistance as mentioned above. The sensitivity for mutation assessment of the assay is 10% mutant allele in a background of normal alleles in the macro-dissected area.

This test was developed and its performance characteristics have been determined by Quest Diagnostics Nichols Institute, San Juan Capistrano. Performance characteristics refer to the analytical performance of the test.

A complete copy of the report is available in the Department of Pathology for review.

Testing performed at Nichols Institute, 33608 Ortega Hwy, San Juan Capistrano, CA 92690.

KRAS MUTATION ANALYSIS

RESULT: NOT DETECTED

Reference Range: Not detected
Specimen Source: Lung upper lobe
Paraffin block number : RS17-217 A3

Based on Sanger sequencing analysis, no mutations were detected in KRAS exons 2 and 3 including codons 12, 13 and 61.

Activating KRAS oncogenic mutations are detected in a wide variety of cancers including 30 - 45% of colorectal carcinoma, 25 -35% of lung adenocarcinomas, and 60-90% of pancreatic cancer. Presence of KRAS mutation in most tumor types is associated with adverse prognosis as well as resistance to receptor tyrosine kinase-directed targeted therapies, including against EGFR.

A complete copy of the report is available in the Department of Pathology for review.

Testing performed at Quest Diagnostics Nichols Institute, 33608 Ortega Highway, San Juan Capistrano, California 92675.

LUNG CA (NSCLC), ALK, FISH

Specimen type:Paraffin embedded tumor tissue
Clinical indication: Lung adenocarcinoma
Method:FISH

PATIENT NAME: BARNARD,CHRISTINE MARIE ACCOUNT #:

BARNARD, CHRISTINE (id #2015, dob: 08/17/1954)

RESULT: POSITIVE FOR ALK REARRANGEMENT

INTERPRETATION:

This FISH analysis was consistent with a rearrangement of the ALK gene in 90% of interphase cells examined.

In non-small cell lung carcinoma, overexpression of the ALK kinase is seen most commonly through an inversion producing ELM4-ALK fusion protein. This test is indicated as an aid in the assessment of patients for whom treatment with ALK inhibitors are being considered. Correlation with clinical findings and other laboratory studies is indicated.

Please expect the result of any other concurrent test in a separate report.

nuc ish (5 ' ' ALKx1-4, 3 ' ' ALKx2-8) (5 ' ' ALK con 3 ' ' ALKx1-4) [45/50]

A complete copy of this report is available in the Department of Pathology Office for review.

Performed by Quest Diagnostics Nichols Institute, 33608 Ortega Highway, San Juan Capistrano, California 92675.

Lung CA (NSCLC) ROS1, FISH:

Specimen type: Tumor embedded paraffin tissue

Clinical indication: Lung adenocarcinoma

RESULT: NEGATIVE FOR ROS1 REARRANGEMENT

Interpretation:

This FISH analysis did not reveal rearrangement in the ROS1 region.

An approximately 5% of tumors with ROS1 rearrangement demonstrated by other methods may not be detected by this assay. This result does not rule out a malignancy or other genetic changes. Correlation with other clinical and laboratory findings is indicated.

Method: FISH

Total cells: 50

Images captured: 2

RESULT:

nuc ish (ROS1 x2) [50]

A complete copy of the report is available in the Department of Pathology for review.

Testing performed by Quest Diagnostics Nichols Institute,

PATIENT NAME: BARNARD,CHRISTINE MARIE ACCOUNT #:

Denver Patient Care Inquiry (PCI: OE Database COCYE)

BARNARD, CHRISTINE (id #2015, dob: 08/17/1954)

33608 Ortega Highway, San Juan Capistrano, California 92675.

Signed Electronically by: Frank Moore, MD, 1/30/2017

Addendum Comment

This addendum is made to include synoptic details for this case.

Synoptic Report

Specimen: Left upper and left lower lobes

Procedure: Wedge excision

Specimen integrity: Intact

Specimen laterality: Left

Tumor site: Left upper and left lower lobes

Tumor size: Up to 1.1 cm

Tumor focality: Multiple

Histologic type: Adenocarcinoma (acinar subtype)

Histologic grade: Well-differentiated

Visceral pleura invasion: Present

Tumor extension: Pleural involvement (separately submitted)

Surgical margins:

Bronchial margin: Negative

Vascular margin: Negative

Parenchymal margin: Negative

Parietal pleural margin: Involved

Chest wall margin: Negative

Tumor distance from closest margin: 0.1 cm from surgical margin

Treatment effect: Negative

Atelectasis or obstructive pneumonia: Negative

Lymph/vascular invasion: Negative

Lymph nodes: Not submitted

Pathologic staging: pT2(m), Nx, Mx

FNM

Signed Electronically by: Frank Moore, MD 6/23/2017

Original Diagnosis:

A. Lung, left superior upper lobe, wedge biopsy:

- Well differentiated adenocarcinoma (acinar type)

B. Lung, left superior lower lobe, wedge biopsy:

- Well differentiated adenocarcinoma (acinar type)

PATIENT NAME: BARNARD,CHRISTINE MARIE

ACCOUNT #:

Denver Patient Care Inquiry (PCI: OE Database COCYE)

BARNARD, CHRISTINE (id #2015, dob: 08/17/1954)

C. Pleura, biopsy:
- Well differentiated adenocarcinoma (acinar type)

—
PATIENT NAME: BARNARD, CHRISTINE M.
ACCESSION #: RS17-217
MRN: AM00132890 ENCOUNTER: AM3006802492
DOB: 8/17/1954 (Age: 62) SEX: F
SUBMITTING PHYSICIAN: RICHARD K PARKER
DATE COLLECTED: 1/16/2017
DATE RECEIVED: 1/16/2017
DATE ACCESSIONED: 1/16/2017
DATE REPORTED: 1/17/2017
—

Performing laboratory location:

Technical processing:
AmeriPath Colorado
Dr M. Pushchak, Medical Director
6750 W. 52nd Ave
Arvada, CO 80002
720.898.3300 Fax 720.898.3333
END OF REPORT

DD:01/16/17 0932 DT:01/17/17 1715

Frank N Moore MD

Electronically Signed by Frank N Moore MD on 06/23/17 at 1522

PATIENT NAME: BARNARD,CHRISTINE MARIE ACCOUNT #:

Denver Patient Care Inquiry (PCI: OE Database COCYE)